activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	2470292	CHEMBL987212	Inhibition of NEK1 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL5855	Homo sapiens	INH	%	10.0
	2470292	CHEMBL987212	Inhibition of NEK1 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL5855	Homo sapiens	INH	%	10.0
	2511988	CHEMBL973481	Inhibition of NEK1 at 1 uM	B	CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1		CHEMBL508307	=	Inhibition	%	29.0	CHEMBL5855	Homo sapiens	INH	%	29.0
	2902778	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902779	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902780	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902781	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902782	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902783	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902784	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902785	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902786	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902787	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902788	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902789	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902790	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	3900.0	CHEMBL5855	Homo sapiens	Kd	nM	3900.0
	2902791	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902792	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902793	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902794	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902795	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902796	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902797	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902798	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902799	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902800	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902801	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902802	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902803	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902804	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902805	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902806	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902807	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902808	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902809	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902810	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	860.0	CHEMBL5855	Homo sapiens	Kd	nM	860.0
	2902811	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902812	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902813	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902814	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2902815	CHEMBL1062846	Binding constant for NEK1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	2921245	CHEMBL1048293	Inhibition of NEK1 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	2938476	CHEMBL1041389	Inhibition of NEK1 at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	6.0	CHEMBL5855	Homo sapiens	INH	%	6.0
	2992229	CHEMBL1044533	Inhibition of human NEK1 at 20 uM by FRET assay	B	C#Cn1c(C#CCCO)nc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL576620	=	Inhibition	%	11.0	CHEMBL5855	Homo sapiens	INH	%	11.0
	3052416	CHEMBL1043343	Residual activity of NEK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	93.0	CHEMBL5855	Homo sapiens	Residual activity	%	93.0
	3052668	CHEMBL1041155	Residual activity of NEK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	94.0	CHEMBL5855	Homo sapiens	Residual activity	%	94.0
	3053977	CHEMBL1050308	Residual activity of NEK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	101.0	CHEMBL5855	Homo sapiens	Residual activity	%	101.0
	3054229	CHEMBL1043343	Residual activity of NEK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	87.0	CHEMBL5855	Homo sapiens	Residual activity	%	87.0
	3055516	CHEMBL1041155	Residual activity of NEK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	85.0	CHEMBL5855	Homo sapiens	Residual activity	%	85.0
	3056821	CHEMBL1050308	Residual activity of NEK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	104.0	CHEMBL5855	Homo sapiens	Residual activity	%	104.0
	3057073	CHEMBL1043343	Residual activity of NEK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	98.0	CHEMBL5855	Homo sapiens	Residual activity	%	98.0
	3058393	CHEMBL1041155	Residual activity of NEK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	85.0	CHEMBL5855	Homo sapiens	Residual activity	%	85.0
	3059677	CHEMBL1050308	Residual activity of NEK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	93.0	CHEMBL5855	Homo sapiens	Residual activity	%	93.0
	3213982	CHEMBL1116730	Inhibition of NEK1 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	-2.0	CHEMBL5855	Homo sapiens	INH	%	-2.0
	3224895	CHEMBL1100973	Inhibition of NEK1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3226274	CHEMBL1100973	Inhibition of NEK1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3332052	CHEMBL1166590	Inhibition of NEK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3333467	CHEMBL1166590	Inhibition of NEK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3334872	CHEMBL1166590	Inhibition of NEK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3336292	CHEMBL1166590	Inhibition of NEK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3339178	CHEMBL1166590	Inhibition of NEK1 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3340481	CHEMBL1166590	Inhibition of NEK1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3341834	CHEMBL1166590	Inhibition of NEK1 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3343281	CHEMBL1166590	Inhibition of NEK1 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3358697	CHEMBL1174939	Inhibition of NEK1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	77.0	CHEMBL5855	Homo sapiens	INH	%	77.0
	3359139	CHEMBL1174939	Inhibition of NEK1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3443461	CHEMBL1244227	Inhibition of NEK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	2.0	CHEMBL5855	Homo sapiens	INH	%	2.0
	3443678	CHEMBL1244227	Inhibition of NEK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	45.0	CHEMBL5855	Homo sapiens	INH	%	45.0
	3444833	CHEMBL1244227	Inhibition of NEK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	44.0	CHEMBL5855	Homo sapiens	INH	%	44.0
	3445222	CHEMBL1244536	Binding affinity to NEK1	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	2500.0	CHEMBL5855	Homo sapiens	Kd	nM	2500.0
	3445457	CHEMBL1244227	Inhibition of NEK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	31.0	CHEMBL5855	Homo sapiens	INH	%	31.0
	3445674	CHEMBL1244227	Inhibition of NEK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	15.0	CHEMBL5855	Homo sapiens	INH	%	15.0
	3445875	CHEMBL1244227	Inhibition of NEK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	38.0	CHEMBL5855	Homo sapiens	INH	%	38.0
	3446065	CHEMBL1244227	Inhibition of NEK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	3448528	CHEMBL1244536	Binding affinity to NEK1	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	3449758	CHEMBL1244536	Binding affinity to NEK1	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	3450161	CHEMBL1244536	Binding affinity to NEK1	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	3450369	CHEMBL1244536	Binding affinity to NEK1	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	3450817	CHEMBL1244536	Binding affinity to NEK1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	3451076	CHEMBL1244536	Binding affinity to NEK1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	uM	10.0
	3463295	CHEMBL1252498	Inhibition of NEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	44.0	CHEMBL5855	Homo sapiens	INH	%	44.0
	3463839	CHEMBL1252498	Inhibition of NEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	18.0	CHEMBL5855	Homo sapiens	INH	%	18.0
	3464058	CHEMBL1252498	Inhibition of NEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	92.0	CHEMBL5855	Homo sapiens	INH	%	92.0
	3559309	CHEMBL1286643	Inhibition of NEK1 after 1 hr at room temperature by caliper method	B	COc1cc(-c2cnc(N)c(N3CC[C@@H](C(=O)O)[C@@H](C)[C@H]3C)n2)cc(OC)c1OC		CHEMBL1276848	=	IC50	nM	170.0	CHEMBL5855	Homo sapiens	IC50	uM	0.17
	3559311	CHEMBL1286643	Inhibition of NEK1 after 1 hr at room temperature by caliper method	B	CCc1ccsc1-c1cnc(N)c(N2CCC(C(=O)O)CC2)n1		CHEMBL1277019	=	IC50	nM	22500.0	CHEMBL5855	Homo sapiens	IC50	uM	22.5
	3559693	CHEMBL1286643	Inhibition of NEK1 after 1 hr at room temperature by caliper method	B	COc1cc(-c2cnc(N)c(N3CCC(C(=O)O)CC3)n2)cc(OC)c1OC		CHEMBL1231522	=	IC50	nM	2600.0	CHEMBL5855	Homo sapiens	IC50	uM	2.6
	6167661	CHEMBL1769202	Inhibition of NEK1	B	CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1		CHEMBL1765781	>	Ki	nM	1000.0	CHEMBL5855	Homo sapiens	Ki	uM	1.0
	6173419	CHEMBL1768228	Inhibition of NEK1 at 25 uM by TR-FRET assay	B	NC(=O)c1ccsc1NC(=O)Cc1csc2ccccc12		CHEMBL1767254	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	6340001	CHEMBL1827239	Activity of NEK1 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	86.0	CHEMBL5855	Homo sapiens	Activity	%	86.0
	7567467	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7567484	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7567955	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7568423	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	=	Kd	nM	8300.0	CHEMBL5855	Homo sapiens	Kd	nM	8300.0
	7568855	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7569458	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7569930	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7570393	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7570820	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7570974	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7571431	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7571907	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7572370	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7572786	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7572955	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7573412	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7573888	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7574357	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7574933	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7575394	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7575865	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7576296	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	=	Kd	nM	3800.0	CHEMBL5855	Homo sapiens	Kd	nM	3800.0
	7576907	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7577366	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7577872	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7578277	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	3400.0	CHEMBL5855	Homo sapiens	Kd	nM	3400.0
	7578915	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7579289	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7579739	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7579771	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	3100.0	CHEMBL5855	Homo sapiens	Kd	nM	3100.0
	7580240	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7580643	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7581273	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7581658	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7582132	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7582596	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7582996	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7584019	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7584490	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7584952	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	170.0	CHEMBL5855	Homo sapiens	Kd	nM	170.0
	7585356	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7585507	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7585915	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7586361	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7586832	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7587286	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7587468	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7587887	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7588340	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7588811	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7589262	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7589433	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7589857	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	2500.0	CHEMBL5855	Homo sapiens	Kd	nM	2500.0
	7590324	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7590798	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7591406	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7591828	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7592300	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	=	Kd	nM	1800.0	CHEMBL5855	Homo sapiens	Kd	nM	1800.0
	7592784	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7593373	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	5200.0	CHEMBL5855	Homo sapiens	Kd	nM	5200.0
	7593808	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7594280	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7594311	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7594763	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7595341	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7595785	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7596288	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7596735	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7597313	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7597797	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7598267	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5855	Homo sapiens	Kd	nM	10000.0
	7598709	CHEMBL1908765	Binding constant for NEK1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	860.0	CHEMBL5855	Homo sapiens	Kd	nM	860.0
	7992207	CHEMBL1935872	Inhibition of NEK1 at 1 uM	B	CN(c1ccccc1-c1cc(Cl)c2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934353	=	Inhibition	%	13.0	CHEMBL5855	Homo sapiens	INH	%	13.0
	8003588	CHEMBL1942752	Inhibition of human NEK1 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940980	<	Inhibition	%	35.0	CHEMBL5855	Homo sapiens	INH	%	35.0
	8003589	CHEMBL1942752	Inhibition of human NEK1 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940981	<	Inhibition	%	35.0	CHEMBL5855	Homo sapiens	INH	%	35.0
	8003590	CHEMBL1942752	Inhibition of human NEK1 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940987	<	Inhibition	%	35.0	CHEMBL5855	Homo sapiens	INH	%	35.0
	8003591	CHEMBL1942752	Inhibition of human NEK1 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940990	<	Inhibition	%	35.0	CHEMBL5855	Homo sapiens	INH	%	35.0
	8061324	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.3	CHEMBL5855	Homo sapiens	Inhibition	%	0.3
	8061501	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-0.61	CHEMBL5855	Homo sapiens	Inhibition	%	-0.61
	8061832	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	2.29	CHEMBL5855	Homo sapiens	Inhibition	%	2.29
	8062023	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	2.09	CHEMBL5855	Homo sapiens	Inhibition	%	2.09
	8062363	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	1.82	CHEMBL5855	Homo sapiens	Inhibition	%	1.82
	8062525	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	5.56	CHEMBL5855	Homo sapiens	Inhibition	%	5.56
	8062749	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	2.46	CHEMBL5855	Homo sapiens	Inhibition	%	2.46
	8062847	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.07	CHEMBL5855	Homo sapiens	Inhibition	%	0.07
	8063203	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	1.09	CHEMBL5855	Homo sapiens	Inhibition	%	1.09
	8063370	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	1.43	CHEMBL5855	Homo sapiens	Inhibition	%	1.43
	8063702	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.34	CHEMBL5855	Homo sapiens	Inhibition	%	1.34
	8063884	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.05	CHEMBL5855	Homo sapiens	Inhibition	%	1.05
	8064108	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.52	CHEMBL5855	Homo sapiens	Inhibition	%	1.52
	8064223	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	3.22	CHEMBL5855	Homo sapiens	Inhibition	%	3.22
	8064433	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	1.22	CHEMBL5855	Homo sapiens	Inhibition	%	1.22
	8064657	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.34	CHEMBL5855	Homo sapiens	Inhibition	%	0.34
	8064795	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	0.52	CHEMBL5855	Homo sapiens	Inhibition	%	0.52
	8064961	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	2.51	CHEMBL5855	Homo sapiens	Inhibition	%	2.51
	8065185	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.44	CHEMBL5855	Homo sapiens	Inhibition	%	0.44
	8065301	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	3.26	CHEMBL5855	Homo sapiens	Inhibition	%	3.26
	8065700	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.83	CHEMBL5855	Homo sapiens	Inhibition	%	0.83
	8065815	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	1.17	CHEMBL5855	Homo sapiens	Inhibition	%	1.17
	8066249	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.36	CHEMBL5855	Homo sapiens	Inhibition	%	0.36
	8066385	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	5.19	CHEMBL5855	Homo sapiens	Inhibition	%	5.19
	8066775	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	2.1	CHEMBL5855	Homo sapiens	Inhibition	%	2.1
	8066899	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.6	CHEMBL5855	Homo sapiens	Inhibition	%	2.6
	8067123	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.19	CHEMBL5855	Homo sapiens	Inhibition	%	2.19
	8067298	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.08	CHEMBL5855	Homo sapiens	Inhibition	%	2.08
	8067419	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	4.28	CHEMBL5855	Homo sapiens	Inhibition	%	4.28
	8067643	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	1.98	CHEMBL5855	Homo sapiens	Inhibition	%	1.98
	8067853	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.55	CHEMBL5855	Homo sapiens	Inhibition	%	1.55
	8067988	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	2.05	CHEMBL5855	Homo sapiens	Inhibition	%	2.05
	8068212	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	19.3	CHEMBL5855	Homo sapiens	Inhibition	%	19.3
	8068376	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.6	CHEMBL5855	Homo sapiens	Inhibition	%	1.6
	8068725	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	9.69	CHEMBL5855	Homo sapiens	Inhibition	%	9.69
	8068899	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.85	CHEMBL5855	Homo sapiens	Inhibition	%	1.85
	8069248	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	1.91	CHEMBL5855	Homo sapiens	Inhibition	%	1.91
	8069543	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	1.28	CHEMBL5855	Homo sapiens	Inhibition	%	1.28
	8069704	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	2.44	CHEMBL5855	Homo sapiens	Inhibition	%	2.44
	8070054	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	3.09	CHEMBL5855	Homo sapiens	Inhibition	%	3.09
	8070226	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.1	CHEMBL5855	Homo sapiens	Inhibition	%	1.1
	8070575	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.4	CHEMBL5855	Homo sapiens	Inhibition	%	0.4
	8070873	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	11.41	CHEMBL5855	Homo sapiens	Inhibition	%	11.41
	8071030	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.58	CHEMBL5855	Homo sapiens	Inhibition	%	1.58
	8071254	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	2.35	CHEMBL5855	Homo sapiens	Inhibition	%	2.35
	8071380	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	2.07	CHEMBL5855	Homo sapiens	Inhibition	%	2.07
	8071553	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.54	CHEMBL5855	Homo sapiens	Inhibition	%	1.54
	8071777	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	2.9	CHEMBL5855	Homo sapiens	Inhibition	%	2.9
	8071902	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.95	CHEMBL5855	Homo sapiens	Inhibition	%	0.95
	8072216	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.22	CHEMBL5855	Homo sapiens	Inhibition	%	-0.22
	8072597	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.46	CHEMBL5855	Homo sapiens	Inhibition	%	1.46
	8072722	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	2.35	CHEMBL5855	Homo sapiens	Inhibition	%	2.35
	8073113	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.85	CHEMBL5855	Homo sapiens	Inhibition	%	1.85
	8073238	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.14	CHEMBL5855	Homo sapiens	Inhibition	%	1.14
	8073462	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.38	CHEMBL5855	Homo sapiens	Inhibition	%	1.38
	8073581	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-0.29	CHEMBL5855	Homo sapiens	Inhibition	%	-0.29
	8073814	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	2.32	CHEMBL5855	Homo sapiens	Inhibition	%	2.32
	8074190	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.92	CHEMBL5855	Homo sapiens	Inhibition	%	1.92
	8074320	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.82	CHEMBL5855	Homo sapiens	Inhibition	%	0.82
	8074544	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	4.81	CHEMBL5855	Homo sapiens	Inhibition	%	4.81
	8074701	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.64	CHEMBL5855	Homo sapiens	Inhibition	%	1.64
	8075052	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.11	CHEMBL5855	Homo sapiens	Inhibition	%	-0.11
	8075163	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	1.65	CHEMBL5855	Homo sapiens	Inhibition	%	1.65
	8075387	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.93	CHEMBL5855	Homo sapiens	Inhibition	%	0.93
	8075400	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	0.5	CHEMBL5855	Homo sapiens	Inhibition	%	0.5
	8075624	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	2.97	CHEMBL5855	Homo sapiens	Inhibition	%	2.97
	8075765	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	2.39	CHEMBL5855	Homo sapiens	Inhibition	%	2.39
	8076131	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	8.29	CHEMBL5855	Homo sapiens	Inhibition	%	8.29
	8076279	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	4.11	CHEMBL5855	Homo sapiens	Inhibition	%	4.11
	8076637	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.84	CHEMBL5855	Homo sapiens	Inhibition	%	0.84
	8076963	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.52	CHEMBL5855	Homo sapiens	Inhibition	%	0.52
	8077210	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	1.61	CHEMBL5855	Homo sapiens	Inhibition	%	1.61
	8077338	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.69	CHEMBL5855	Homo sapiens	Inhibition	%	1.69
	8077562	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	1.56	CHEMBL5855	Homo sapiens	Inhibition	%	1.56
	8077713	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	43.02	CHEMBL5855	Homo sapiens	Inhibition	%	43.02
	8077856	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.71	CHEMBL5855	Homo sapiens	Inhibition	%	1.71
	8078080	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.3	CHEMBL5855	Homo sapiens	Inhibition	%	1.3
	8078219	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-0.93	CHEMBL5855	Homo sapiens	Inhibition	%	-0.93
	8078545	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.37	CHEMBL5855	Homo sapiens	Inhibition	%	0.37
	8078795	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	17.23	CHEMBL5855	Homo sapiens	Inhibition	%	17.23
	8079135	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	4.44	CHEMBL5855	Homo sapiens	Inhibition	%	4.44
	8079293	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	13.59	CHEMBL5855	Homo sapiens	Inhibition	%	13.59
	8079659	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.95	CHEMBL5855	Homo sapiens	Inhibition	%	1.95
	8079798	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-1.21	CHEMBL5855	Homo sapiens	Inhibition	%	-1.21
	8080127	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-0.17	CHEMBL5855	Homo sapiens	Inhibition	%	-0.17
	8080379	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	-1.61	CHEMBL5855	Homo sapiens	Inhibition	%	-1.61
	8080718	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.79	CHEMBL5855	Homo sapiens	Inhibition	%	0.79
	8080882	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	54.95	CHEMBL5855	Homo sapiens	Inhibition	%	54.95
	8081241	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	2.41	CHEMBL5855	Homo sapiens	Inhibition	%	2.41
	8081385	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	4.68	CHEMBL5855	Homo sapiens	Inhibition	%	4.68
	8081609	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	21.61	CHEMBL5855	Homo sapiens	Inhibition	%	21.61
	8081712	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.25	CHEMBL5855	Homo sapiens	Inhibition	%	0.25
	8081964	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	2.33	CHEMBL5855	Homo sapiens	Inhibition	%	2.33
	8082301	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	4.16	CHEMBL5855	Homo sapiens	Inhibition	%	4.16
	8082474	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-2.75	CHEMBL5855	Homo sapiens	Inhibition	%	-2.75
	8082698	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.36	CHEMBL5855	Homo sapiens	Inhibition	%	0.36
	8082821	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.93	CHEMBL5855	Homo sapiens	Inhibition	%	0.93
	8083201	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	2.1	CHEMBL5855	Homo sapiens	Inhibition	%	2.1
	8083300	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.17	CHEMBL5855	Homo sapiens	Inhibition	%	0.17
	8083524	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.75	CHEMBL5855	Homo sapiens	Inhibition	%	0.75
	8083554	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-1.33	CHEMBL5855	Homo sapiens	Inhibition	%	-1.33
	8083778	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	0.56	CHEMBL5855	Homo sapiens	Inhibition	%	0.56
	8083888	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	-0.73	CHEMBL5855	Homo sapiens	Inhibition	%	-0.73
	8084297	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	1.98	CHEMBL5855	Homo sapiens	Inhibition	%	1.98
	8084415	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	3.06	CHEMBL5855	Homo sapiens	Inhibition	%	3.06
	8084639	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.59	CHEMBL5855	Homo sapiens	Inhibition	%	0.59
	8084800	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	4.83	CHEMBL5855	Homo sapiens	Inhibition	%	4.83
	8085122	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	1.07	CHEMBL5855	Homo sapiens	Inhibition	%	1.07
	8085378	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-1.23	CHEMBL5855	Homo sapiens	Inhibition	%	-1.23
	8085486	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.96	CHEMBL5855	Homo sapiens	Inhibition	%	0.96
	8085710	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	1.95	CHEMBL5855	Homo sapiens	Inhibition	%	1.95
	8085899	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	5.54	CHEMBL5855	Homo sapiens	Inhibition	%	5.54
	8086238	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	2.49	CHEMBL5855	Homo sapiens	Inhibition	%	2.49
	8086400	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	2.56	CHEMBL5855	Homo sapiens	Inhibition	%	2.56
	8086723	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.01	CHEMBL5855	Homo sapiens	Inhibition	%	1.01
	8086934	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	2.78	CHEMBL5855	Homo sapiens	Inhibition	%	2.78
	8087316	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.34	CHEMBL5855	Homo sapiens	Inhibition	%	2.34
	8087430	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.74	CHEMBL5855	Homo sapiens	Inhibition	%	2.74
	8087654	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	3.62	CHEMBL5855	Homo sapiens	Inhibition	%	3.62
	8087792	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.68	CHEMBL5855	Homo sapiens	Inhibition	%	2.68
	8088158	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	3.76	CHEMBL5855	Homo sapiens	Inhibition	%	3.76
	8088306	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.84	CHEMBL5855	Homo sapiens	Inhibition	%	1.84
	8088658	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	4.69	CHEMBL5855	Homo sapiens	Inhibition	%	4.69
	8088975	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.6	CHEMBL5855	Homo sapiens	Inhibition	%	2.6
	8089103	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.59	CHEMBL5855	Homo sapiens	Inhibition	%	0.59
	8089475	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.48	CHEMBL5855	Homo sapiens	Inhibition	%	0.48
	8089595	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	1.1	CHEMBL5855	Homo sapiens	Inhibition	%	1.1
	8089819	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.72	CHEMBL5855	Homo sapiens	Inhibition	%	0.72
	8089999	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.62	CHEMBL5855	Homo sapiens	Inhibition	%	-0.62
	8090164	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.53	CHEMBL5855	Homo sapiens	Inhibition	%	2.53
	8090388	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	6.64	CHEMBL5855	Homo sapiens	Inhibition	%	6.64
	8090555	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.82	CHEMBL5855	Homo sapiens	Inhibition	%	1.82
	8090694	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	1.31	CHEMBL5855	Homo sapiens	Inhibition	%	1.31
	8090918	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.8	CHEMBL5855	Homo sapiens	Inhibition	%	0.8
	8091123	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	2.22	CHEMBL5855	Homo sapiens	Inhibition	%	2.22
	8091260	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.83	CHEMBL5855	Homo sapiens	Inhibition	%	1.83
	8091484	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	3.93	CHEMBL5855	Homo sapiens	Inhibition	%	3.93
	8091639	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.64	CHEMBL5855	Homo sapiens	Inhibition	%	2.64
	8091979	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	3.0	CHEMBL5855	Homo sapiens	Inhibition	%	3.0
	8092116	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	1.07	CHEMBL5855	Homo sapiens	Inhibition	%	1.07
	8092491	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	3.08	CHEMBL5855	Homo sapiens	Inhibition	%	3.08
	8092639	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.25	CHEMBL5855	Homo sapiens	Inhibition	%	1.25
	8092863	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	2.04	CHEMBL5855	Homo sapiens	Inhibition	%	2.04
	8092992	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	19.33	CHEMBL5855	Homo sapiens	Inhibition	%	19.33
	8093304	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	-0.37	CHEMBL5855	Homo sapiens	Inhibition	%	-0.37
	8093444	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.62	CHEMBL5855	Homo sapiens	Inhibition	%	0.62
	8093668	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	0.04	CHEMBL5855	Homo sapiens	Inhibition	%	0.04
	8093807	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	2.3	CHEMBL5855	Homo sapiens	Inhibition	%	2.3
	8094151	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	4.41	CHEMBL5855	Homo sapiens	Inhibition	%	4.41
	8094331	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.34	CHEMBL5855	Homo sapiens	Inhibition	%	1.34
	8094730	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	3.16	CHEMBL5855	Homo sapiens	Inhibition	%	3.16
	8094886	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.68	CHEMBL5855	Homo sapiens	Inhibition	%	1.68
	8095250	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	2.63	CHEMBL5855	Homo sapiens	Inhibition	%	2.63
	8095453	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	2.22	CHEMBL5855	Homo sapiens	Inhibition	%	2.22
	8095818	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	8.78	CHEMBL5855	Homo sapiens	Inhibition	%	8.78
	8095966	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	1.6	CHEMBL5855	Homo sapiens	Inhibition	%	1.6
	8096307	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	1.2	CHEMBL5855	Homo sapiens	Inhibition	%	1.2
	8096446	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	1.73	CHEMBL5855	Homo sapiens	Inhibition	%	1.73
	8096670	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.94	CHEMBL5855	Homo sapiens	Inhibition	%	0.94
	8096826	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	5.81	CHEMBL5855	Homo sapiens	Inhibition	%	5.81
	8097197	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	2.57	CHEMBL5855	Homo sapiens	Inhibition	%	2.57
	8097284	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	24.77	CHEMBL5855	Homo sapiens	Inhibition	%	24.77
	8097504	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.3	CHEMBL5855	Homo sapiens	Inhibition	%	0.3
	8097878	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	3.08	CHEMBL5855	Homo sapiens	Inhibition	%	3.08
	8098011	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.04	CHEMBL5855	Homo sapiens	Inhibition	%	0.04
	8098355	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.41	CHEMBL5855	Homo sapiens	Inhibition	%	0.41
	8098535	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.67	CHEMBL5855	Homo sapiens	Inhibition	%	1.67
	8098759	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.6	CHEMBL5855	Homo sapiens	Inhibition	%	0.6
	8098944	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	11.15	CHEMBL5855	Homo sapiens	Inhibition	%	11.15
	8099088	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	2.15	CHEMBL5855	Homo sapiens	Inhibition	%	2.15
	8099312	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	3.07	CHEMBL5855	Homo sapiens	Inhibition	%	3.07
	8099454	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.21	CHEMBL5855	Homo sapiens	Inhibition	%	2.21
	8099648	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.87	CHEMBL5855	Homo sapiens	Inhibition	%	0.87
	8100019	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	5.55	CHEMBL5855	Homo sapiens	Inhibition	%	5.55
	8100165	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	0.76	CHEMBL5855	Homo sapiens	Inhibition	%	0.76
	8100389	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	0.9	CHEMBL5855	Homo sapiens	Inhibition	%	0.9
	8100505	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.2	CHEMBL5855	Homo sapiens	Inhibition	%	3.2
	8100869	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.52	CHEMBL5855	Homo sapiens	Inhibition	%	0.52
	8101029	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	3.59	CHEMBL5855	Homo sapiens	Inhibition	%	3.59
	8101395	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-1.04	CHEMBL5855	Homo sapiens	Inhibition	%	-1.04
	8101580	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	4.81	CHEMBL5855	Homo sapiens	Inhibition	%	4.81
	8101833	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	1.94	CHEMBL5855	Homo sapiens	Inhibition	%	1.94
	8102057	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	10.55	CHEMBL5855	Homo sapiens	Inhibition	%	10.55
	8102212	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	0.79	CHEMBL5855	Homo sapiens	Inhibition	%	0.79
	8102343	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	2.1	CHEMBL5855	Homo sapiens	Inhibition	%	2.1
	8102567	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	-0.43	CHEMBL5855	Homo sapiens	Inhibition	%	-0.43
	8102687	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	4.13	CHEMBL5855	Homo sapiens	Inhibition	%	4.13
	8103089	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	1.07	CHEMBL5855	Homo sapiens	Inhibition	%	1.07
	8103285	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	2.39	CHEMBL5855	Homo sapiens	Inhibition	%	2.39
	8103647	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	2.58	CHEMBL5855	Homo sapiens	Inhibition	%	2.58
	8103797	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.9	CHEMBL5855	Homo sapiens	Inhibition	%	1.9
	8103982	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	2.03	CHEMBL5855	Homo sapiens	Inhibition	%	2.03
	8104206	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.97	CHEMBL5855	Homo sapiens	Inhibition	%	0.97
	8104354	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	9.78	CHEMBL5855	Homo sapiens	Inhibition	%	9.78
	8104724	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	-0.1	CHEMBL5855	Homo sapiens	Inhibition	%	-0.1
	8104838	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.19	CHEMBL5855	Homo sapiens	Inhibition	%	2.19
	8105062	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.49	CHEMBL5855	Homo sapiens	Inhibition	%	2.49
	8105202	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.52	CHEMBL5855	Homo sapiens	Inhibition	%	0.52
	8105368	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	6.47	CHEMBL5855	Homo sapiens	Inhibition	%	6.47
	8105592	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	9.13	CHEMBL5855	Homo sapiens	Inhibition	%	9.13
	8105730	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	1.71	CHEMBL5855	Homo sapiens	Inhibition	%	1.71
	8106010	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.85	CHEMBL5855	Homo sapiens	Inhibition	%	1.85
	8106399	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.23	CHEMBL5855	Homo sapiens	Inhibition	%	2.23
	8106555	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	8.86	CHEMBL5855	Homo sapiens	Inhibition	%	8.86
	8106908	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.95	CHEMBL5855	Homo sapiens	Inhibition	%	1.95
	8107029	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.35	CHEMBL5855	Homo sapiens	Inhibition	%	1.35
	8107253	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.82	CHEMBL5855	Homo sapiens	Inhibition	%	0.82
	8107425	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	1.03	CHEMBL5855	Homo sapiens	Inhibition	%	1.03
	8107626	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	2.81	CHEMBL5855	Homo sapiens	Inhibition	%	2.81
	8107985	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	5.37	CHEMBL5855	Homo sapiens	Inhibition	%	5.37
	8108143	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	1.76	CHEMBL5855	Homo sapiens	Inhibition	%	1.76
	8108542	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.11	CHEMBL5855	Homo sapiens	Inhibition	%	0.11
	8108689	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	17.64	CHEMBL5855	Homo sapiens	Inhibition	%	17.64
	8109055	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.11	CHEMBL5855	Homo sapiens	Inhibition	%	1.11
	8109393	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	2.12	CHEMBL5855	Homo sapiens	Inhibition	%	2.12
	8109523	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	1.21	CHEMBL5855	Homo sapiens	Inhibition	%	1.21
	8109918	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	38.15	CHEMBL5855	Homo sapiens	Inhibition	%	38.15
	8110050	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	1.83	CHEMBL5855	Homo sapiens	Inhibition	%	1.83
	8110329	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.3	CHEMBL5855	Homo sapiens	Inhibition	%	1.3
	8110719	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	4.09	CHEMBL5855	Homo sapiens	Inhibition	%	4.09
	8110877	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-2.66	CHEMBL5855	Homo sapiens	Inhibition	%	-2.66
	8111224	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	0.6	CHEMBL5855	Homo sapiens	Inhibition	%	0.6
	8111575	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	0.01	CHEMBL5855	Homo sapiens	Inhibition	%	0.01
	8111741	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	1.9	CHEMBL5855	Homo sapiens	Inhibition	%	1.9
	8111946	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	4.04	CHEMBL5855	Homo sapiens	Inhibition	%	4.04
	8112170	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	3.56	CHEMBL5855	Homo sapiens	Inhibition	%	3.56
	8112307	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	1.7	CHEMBL5855	Homo sapiens	Inhibition	%	1.7
	8112475	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.01	CHEMBL5855	Homo sapiens	Inhibition	%	2.01
	8112699	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	1.83	CHEMBL5855	Homo sapiens	Inhibition	%	1.83
	8112871	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.71	CHEMBL5855	Homo sapiens	Inhibition	%	0.71
	8113023	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	54.06	CHEMBL5855	Homo sapiens	Inhibition	%	54.06
	8113247	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	1.96	CHEMBL5855	Homo sapiens	Inhibition	%	1.96
	8113383	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.59	CHEMBL5855	Homo sapiens	Inhibition	%	1.59
	8113731	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	0.4	CHEMBL5855	Homo sapiens	Inhibition	%	0.4
	8113847	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.54	CHEMBL5855	Homo sapiens	Inhibition	%	-0.54
	8114071	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.1	CHEMBL5855	Homo sapiens	Inhibition	%	-0.1
	8114247	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	3.08	CHEMBL5855	Homo sapiens	Inhibition	%	3.08
	8114379	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	4.11	CHEMBL5855	Homo sapiens	Inhibition	%	4.11
	8114603	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.98	CHEMBL5855	Homo sapiens	Inhibition	%	1.98
	8114655	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.91	CHEMBL5855	Homo sapiens	Inhibition	%	1.91
	8114879	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.48	CHEMBL5855	Homo sapiens	Inhibition	%	1.48
	8115045	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	4.57	CHEMBL5855	Homo sapiens	Inhibition	%	4.57
	8115210	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-3.17	CHEMBL5855	Homo sapiens	Inhibition	%	-3.17
	8115434	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-2.25	CHEMBL5855	Homo sapiens	Inhibition	%	-2.25
	8115554	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.24	CHEMBL5855	Homo sapiens	Inhibition	%	1.24
	8115911	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	0.55	CHEMBL5855	Homo sapiens	Inhibition	%	0.55
	8116070	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.37	CHEMBL5855	Homo sapiens	Inhibition	%	0.37
	8116294	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	1.29	CHEMBL5855	Homo sapiens	Inhibition	%	1.29
	8116497	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	2.28	CHEMBL5855	Homo sapiens	Inhibition	%	2.28
	8116631	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.2	CHEMBL5855	Homo sapiens	Inhibition	%	-0.2
	8117027	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	3.98	CHEMBL5855	Homo sapiens	Inhibition	%	3.98
	8117198	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	2.1	CHEMBL5855	Homo sapiens	Inhibition	%	2.1
	8117580	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	2.74	CHEMBL5855	Homo sapiens	Inhibition	%	2.74
	8117710	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	1.25	CHEMBL5855	Homo sapiens	Inhibition	%	1.25
	8117934	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	2.81	CHEMBL5855	Homo sapiens	Inhibition	%	2.81
	8118072	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	2.19	CHEMBL5855	Homo sapiens	Inhibition	%	2.19
	8118412	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	2.17	CHEMBL5855	Homo sapiens	Inhibition	%	2.17
	8118584	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	8.21	CHEMBL5855	Homo sapiens	Inhibition	%	8.21
	8118944	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	3.24	CHEMBL5855	Homo sapiens	Inhibition	%	3.24
	8119215	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.77	CHEMBL5855	Homo sapiens	Inhibition	%	1.77
	8119374	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	34.66	CHEMBL5855	Homo sapiens	Inhibition	%	34.66
	8119765	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	1.58	CHEMBL5855	Homo sapiens	Inhibition	%	1.58
	8119884	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-0.13	CHEMBL5855	Homo sapiens	Inhibition	%	-0.13
	8120108	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.85	CHEMBL5855	Homo sapiens	Inhibition	%	1.85
	8120247	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.53	CHEMBL5855	Homo sapiens	Inhibition	%	0.53
	8120631	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	1.14	CHEMBL5855	Homo sapiens	Inhibition	%	1.14
	8120832	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	2.37	CHEMBL5855	Homo sapiens	Inhibition	%	2.37
	8120960	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.8	CHEMBL5855	Homo sapiens	Inhibition	%	0.8
	8121184	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.15	CHEMBL5855	Homo sapiens	Inhibition	%	-0.15
	8121356	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.41	CHEMBL5855	Homo sapiens	Inhibition	%	1.41
	8121523	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	2.1	CHEMBL5855	Homo sapiens	Inhibition	%	2.1
	8121747	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	1.7	CHEMBL5855	Homo sapiens	Inhibition	%	1.7
	8121910	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	1.75	CHEMBL5855	Homo sapiens	Inhibition	%	1.75
	8122255	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-0.38	CHEMBL5855	Homo sapiens	Inhibition	%	-0.38
	8122393	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	0.52	CHEMBL5855	Homo sapiens	Inhibition	%	0.52
	8122737	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	4.16	CHEMBL5855	Homo sapiens	Inhibition	%	4.16
	8122904	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	3.15	CHEMBL5855	Homo sapiens	Inhibition	%	3.15
	8123128	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	5.32	CHEMBL5855	Homo sapiens	Inhibition	%	5.32
	8123270	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	3.95	CHEMBL5855	Homo sapiens	Inhibition	%	3.95
	8123548	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	-0.24	CHEMBL5855	Homo sapiens	Inhibition	%	-0.24
	8123698	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	3.59	CHEMBL5855	Homo sapiens	Inhibition	%	3.59
	8123922	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	15.85	CHEMBL5855	Homo sapiens	Inhibition	%	15.85
	8124089	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	Inhibition	%	0.0
	8124432	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	3.3	CHEMBL5855	Homo sapiens	Inhibition	%	3.3
	8124571	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.72	CHEMBL5855	Homo sapiens	Inhibition	%	1.72
	8124960	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.05	CHEMBL5855	Homo sapiens	Inhibition	%	-0.05
	8125161	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.27	CHEMBL5855	Homo sapiens	Inhibition	%	2.27
	8125515	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.17	CHEMBL5855	Homo sapiens	Inhibition	%	0.17
	8125683	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.96	CHEMBL5855	Homo sapiens	Inhibition	%	1.96
	8126071	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-1.35	CHEMBL5855	Homo sapiens	Inhibition	%	-1.35
	8126235	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	2.24	CHEMBL5855	Homo sapiens	Inhibition	%	2.24
	8126574	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	18.11	CHEMBL5855	Homo sapiens	Inhibition	%	18.11
	8126710	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	2.04	CHEMBL5855	Homo sapiens	Inhibition	%	2.04
	8126934	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	3.28	CHEMBL5855	Homo sapiens	Inhibition	%	3.28
	8127056	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.09	CHEMBL5855	Homo sapiens	Inhibition	%	1.09
	8127447	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	4.05	CHEMBL5855	Homo sapiens	Inhibition	%	4.05
	8127589	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	19.05	CHEMBL5855	Homo sapiens	Inhibition	%	19.05
	8127877	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	2.64	CHEMBL5855	Homo sapiens	Inhibition	%	2.64
	8128253	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	2.11	CHEMBL5855	Homo sapiens	Inhibition	%	2.11
	8128420	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	9.07	CHEMBL5855	Homo sapiens	Inhibition	%	9.07
	8128763	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	18.34	CHEMBL5855	Homo sapiens	Inhibition	%	18.34
	8128900	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.27	CHEMBL5855	Homo sapiens	Inhibition	%	0.27
	8129124	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	1.19	CHEMBL5855	Homo sapiens	Inhibition	%	1.19
	8129295	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.25	CHEMBL5855	Homo sapiens	Inhibition	%	0.25
	8129484	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	1.69	CHEMBL5855	Homo sapiens	Inhibition	%	1.69
	8129847	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.72	CHEMBL5855	Homo sapiens	Inhibition	%	1.72
	8130008	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	2.31	CHEMBL5855	Homo sapiens	Inhibition	%	2.31
	8130232	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.95	CHEMBL5855	Homo sapiens	Inhibition	%	0.95
	8130404	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.79	CHEMBL5855	Homo sapiens	Inhibition	%	-0.79
	8130564	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	2.8	CHEMBL5855	Homo sapiens	Inhibition	%	2.8
	8130788	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	4.48	CHEMBL5855	Homo sapiens	Inhibition	%	4.48
	8130904	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.77	CHEMBL5855	Homo sapiens	Inhibition	%	1.77
	8131267	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.05	CHEMBL5855	Homo sapiens	Inhibition	%	3.05
	8131387	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.58	CHEMBL5855	Homo sapiens	Inhibition	%	1.58
	8131611	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	2.31	CHEMBL5855	Homo sapiens	Inhibition	%	2.31
	8131778	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	5.27	CHEMBL5855	Homo sapiens	Inhibition	%	5.27
	8131919	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	7.14	CHEMBL5855	Homo sapiens	Inhibition	%	7.14
	8132143	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	41.87	CHEMBL5855	Homo sapiens	Inhibition	%	41.87
	8132205	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	11.31	CHEMBL5855	Homo sapiens	Inhibition	%	11.31
	8132429	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.9	CHEMBL5855	Homo sapiens	Inhibition	%	1.9
	8132576	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	5.18	CHEMBL5855	Homo sapiens	Inhibition	%	5.18
	8132744	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-0.35	CHEMBL5855	Homo sapiens	Inhibition	%	-0.35
	8132968	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	1.83	CHEMBL5855	Homo sapiens	Inhibition	%	1.83
	8133089	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.32	CHEMBL5855	Homo sapiens	Inhibition	%	0.32
	8133451	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.55	CHEMBL5855	Homo sapiens	Inhibition	%	1.55
	8133623	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.32	CHEMBL5855	Homo sapiens	Inhibition	%	0.32
	8133803	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	5.21	CHEMBL5855	Homo sapiens	Inhibition	%	5.21
	8134027	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	29.06	CHEMBL5855	Homo sapiens	Inhibition	%	29.06
	8134175	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	0.22	CHEMBL5855	Homo sapiens	Inhibition	%	0.22
	8134559	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.2	CHEMBL5855	Homo sapiens	Inhibition	%	1.2
	8134743	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-1.43	CHEMBL5855	Homo sapiens	Inhibition	%	-1.43
	8135127	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	1.6	CHEMBL5855	Homo sapiens	Inhibition	%	1.6
	8135242	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.04	CHEMBL5855	Homo sapiens	Inhibition	%	3.04
	8135607	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	1.85	CHEMBL5855	Homo sapiens	Inhibition	%	1.85
	8135952	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	1.49	CHEMBL5855	Homo sapiens	Inhibition	%	1.49
	8136120	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.81	CHEMBL5855	Homo sapiens	Inhibition	%	1.81
	8136488	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	3.2	CHEMBL5855	Homo sapiens	Inhibition	%	3.2
	8136778	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.66	CHEMBL5855	Homo sapiens	Inhibition	%	1.66
	8136913	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.09	CHEMBL5855	Homo sapiens	Inhibition	%	0.09
	8137300	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	0.28	CHEMBL5855	Homo sapiens	Inhibition	%	0.28
	8137420	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	19.83	CHEMBL5855	Homo sapiens	Inhibition	%	19.83
	8137644	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-0.56	CHEMBL5855	Homo sapiens	Inhibition	%	-0.56
	8137792	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.21	CHEMBL5855	Homo sapiens	Inhibition	%	1.21
	8137958	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	1.15	CHEMBL5855	Homo sapiens	Inhibition	%	1.15
	8138182	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	2.83	CHEMBL5855	Homo sapiens	Inhibition	%	2.83
	8138361	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.67	CHEMBL5855	Homo sapiens	Inhibition	%	1.67
	8138509	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	3.78	CHEMBL5855	Homo sapiens	Inhibition	%	3.78
	8138733	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.29	CHEMBL5855	Homo sapiens	Inhibition	%	-1.29
	8138891	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.36	CHEMBL5855	Homo sapiens	Inhibition	%	0.36
	8139076	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-2.34	CHEMBL5855	Homo sapiens	Inhibition	%	-2.34
	8139459	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	2.75	CHEMBL5855	Homo sapiens	Inhibition	%	2.75
	8139573	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.71	CHEMBL5855	Homo sapiens	Inhibition	%	1.71
	8139797	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.9	CHEMBL5855	Homo sapiens	Inhibition	%	1.9
	8139938	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	1.83	CHEMBL5855	Homo sapiens	Inhibition	%	1.83
	8140285	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.39	CHEMBL5855	Homo sapiens	Inhibition	%	2.39
	8140444	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	3.93	CHEMBL5855	Homo sapiens	Inhibition	%	3.93
	8140811	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	6.26	CHEMBL5855	Homo sapiens	Inhibition	%	6.26
	8141113	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.31	CHEMBL5855	Homo sapiens	Inhibition	%	1.31
	8141243	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.51	CHEMBL5855	Homo sapiens	Inhibition	%	-0.51
	8141467	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.33	CHEMBL5855	Homo sapiens	Inhibition	%	1.33
	8141627	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	7.87	CHEMBL5855	Homo sapiens	Inhibition	%	7.87
	8141970	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	2.88	CHEMBL5855	Homo sapiens	Inhibition	%	2.88
	8142131	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.11	CHEMBL5855	Homo sapiens	Inhibition	%	0.11
	8142523	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	18.37	CHEMBL5855	Homo sapiens	Inhibition	%	18.37
	8142699	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	3.9	CHEMBL5855	Homo sapiens	Inhibition	%	3.9
	8143072	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.39	CHEMBL5855	Homo sapiens	Inhibition	%	-1.39
	8143227	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	3.38	CHEMBL5855	Homo sapiens	Inhibition	%	3.38
	8143414	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.45	CHEMBL5855	Homo sapiens	Inhibition	%	2.45
	8143638	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.61	CHEMBL5855	Homo sapiens	Inhibition	%	3.61
	8143797	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.11	CHEMBL5855	Homo sapiens	Inhibition	%	3.11
	8144135	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.95	CHEMBL5855	Homo sapiens	Inhibition	%	1.95
	8144274	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	3.84	CHEMBL5855	Homo sapiens	Inhibition	%	3.84
	8144498	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.58	CHEMBL5855	Homo sapiens	Inhibition	%	1.58
	8144628	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	3.41	CHEMBL5855	Homo sapiens	Inhibition	%	3.41
	8144781	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.09	CHEMBL5855	Homo sapiens	Inhibition	%	1.09
	8145005	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	2.25	CHEMBL5855	Homo sapiens	Inhibition	%	2.25
	8145142	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	3.48	CHEMBL5855	Homo sapiens	Inhibition	%	3.48
	8145455	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.0	CHEMBL5855	Homo sapiens	Inhibition	%	1.0
	8145803	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.36	CHEMBL5855	Homo sapiens	Inhibition	%	1.36
	8145964	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	1.38	CHEMBL5855	Homo sapiens	Inhibition	%	1.38
	8146308	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.58	CHEMBL5855	Homo sapiens	Inhibition	%	-0.58
	8146468	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	2.9	CHEMBL5855	Homo sapiens	Inhibition	%	2.9
	8146859	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	60.5	CHEMBL5855	Homo sapiens	Inhibition	%	60.5
	8147028	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	2.33	CHEMBL5855	Homo sapiens	Inhibition	%	2.33
	8147394	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	2.32	CHEMBL5855	Homo sapiens	Inhibition	%	2.32
	8147547	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.7	CHEMBL5855	Homo sapiens	Inhibition	%	2.7
	8147771	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.37	CHEMBL5855	Homo sapiens	Inhibition	%	1.37
	8147958	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	2.53	CHEMBL5855	Homo sapiens	Inhibition	%	2.53
	8148116	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	2.67	CHEMBL5855	Homo sapiens	Inhibition	%	2.67
	8148454	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.93	CHEMBL5855	Homo sapiens	Inhibition	%	1.93
	8148817	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	2.93	CHEMBL5855	Homo sapiens	Inhibition	%	2.93
	8148955	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	4.02	CHEMBL5855	Homo sapiens	Inhibition	%	4.02
	8149338	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.91	CHEMBL5855	Homo sapiens	Inhibition	%	0.91
	8149472	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	5.88	CHEMBL5855	Homo sapiens	Inhibition	%	5.88
	8149696	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	2.71	CHEMBL5855	Homo sapiens	Inhibition	%	2.71
	8149794	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	2.1	CHEMBL5855	Homo sapiens	Inhibition	%	2.1
	8150143	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.66	CHEMBL5855	Homo sapiens	Inhibition	%	0.66
	8150303	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	1.93	CHEMBL5855	Homo sapiens	Inhibition	%	1.93
	8150527	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.52	CHEMBL5855	Homo sapiens	Inhibition	%	-0.52
	8150647	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	1.18	CHEMBL5855	Homo sapiens	Inhibition	%	1.18
	8150812	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.09	CHEMBL5855	Homo sapiens	Inhibition	%	0.09
	8151036	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.97	CHEMBL5855	Homo sapiens	Inhibition	%	0.97
	8151199	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-0.31	CHEMBL5855	Homo sapiens	Inhibition	%	-0.31
	8151376	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	3.3	CHEMBL5855	Homo sapiens	Inhibition	%	3.3
	8151600	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	3.1	CHEMBL5855	Homo sapiens	Inhibition	%	3.1
	8151738	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	2.59	CHEMBL5855	Homo sapiens	Inhibition	%	2.59
	8152116	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.9	CHEMBL5855	Homo sapiens	Inhibition	%	0.9
	8152304	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	2.21	CHEMBL5855	Homo sapiens	Inhibition	%	2.21
	8152462	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.71	CHEMBL5855	Homo sapiens	Inhibition	%	2.71
	8152686	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.57	CHEMBL5855	Homo sapiens	Inhibition	%	2.57
	8152800	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.52	CHEMBL5855	Homo sapiens	Inhibition	%	2.52
	8153163	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.24	CHEMBL5855	Homo sapiens	Inhibition	%	1.24
	8153300	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	5.01	CHEMBL5855	Homo sapiens	Inhibition	%	5.01
	8153524	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	4.64	CHEMBL5855	Homo sapiens	Inhibition	%	4.64
	8153681	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	1.78	CHEMBL5855	Homo sapiens	Inhibition	%	1.78
	8154038	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	5.36	CHEMBL5855	Homo sapiens	Inhibition	%	5.36
	8154135	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.49	CHEMBL5855	Homo sapiens	Inhibition	%	1.49
	8154359	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.18	CHEMBL5855	Homo sapiens	Inhibition	%	2.18
	8154485	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.27	CHEMBL5855	Homo sapiens	Inhibition	%	0.27
	8154868	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-1.06	CHEMBL5855	Homo sapiens	Inhibition	%	-1.06
	8154988	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.48	CHEMBL5855	Homo sapiens	Inhibition	%	0.48
	8155388	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.26	CHEMBL5855	Homo sapiens	Inhibition	%	-0.26
	8155549	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	1.87	CHEMBL5855	Homo sapiens	Inhibition	%	1.87
	8155951	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	4.93	CHEMBL5855	Homo sapiens	Inhibition	%	4.93
	8156089	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	2.34	CHEMBL5855	Homo sapiens	Inhibition	%	2.34
	8156301	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	3.18	CHEMBL5855	Homo sapiens	Inhibition	%	3.18
	8156525	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.85	CHEMBL5855	Homo sapiens	Inhibition	%	1.85
	8156675	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	4.9	CHEMBL5855	Homo sapiens	Inhibition	%	4.9
	8157042	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	5.75	CHEMBL5855	Homo sapiens	Inhibition	%	5.75
	8157162	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.56	CHEMBL5855	Homo sapiens	Inhibition	%	1.56
	8157386	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	2.57	CHEMBL5855	Homo sapiens	Inhibition	%	2.57
	8157527	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	4.76	CHEMBL5855	Homo sapiens	Inhibition	%	4.76
	8157881	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.8	CHEMBL5855	Homo sapiens	Inhibition	%	2.8
	8158042	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	1.56	CHEMBL5855	Homo sapiens	Inhibition	%	1.56
	8158292	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	4.4	CHEMBL5855	Homo sapiens	Inhibition	%	4.4
	8158674	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	2.36	CHEMBL5855	Homo sapiens	Inhibition	%	2.36
	8158843	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	1.23	CHEMBL5855	Homo sapiens	Inhibition	%	1.23
	8159202	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	3.33	CHEMBL5855	Homo sapiens	Inhibition	%	3.33
	8159546	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	2.32	CHEMBL5855	Homo sapiens	Inhibition	%	2.32
	8159677	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	3.43	CHEMBL5855	Homo sapiens	Inhibition	%	3.43
	8160042	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.34	CHEMBL5855	Homo sapiens	Inhibition	%	1.34
	8160179	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	2.42	CHEMBL5855	Homo sapiens	Inhibition	%	2.42
	8160553	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-1.36	CHEMBL5855	Homo sapiens	Inhibition	%	-1.36
	8160847	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	3.91	CHEMBL5855	Homo sapiens	Inhibition	%	3.91
	8160997	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	2.09	CHEMBL5855	Homo sapiens	Inhibition	%	2.09
	8161221	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	4.64	CHEMBL5855	Homo sapiens	Inhibition	%	4.64
	8161364	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	4.85	CHEMBL5855	Homo sapiens	Inhibition	%	4.85
	8161713	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.26	CHEMBL5855	Homo sapiens	Inhibition	%	1.26
	8161851	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	21.81	CHEMBL5855	Homo sapiens	Inhibition	%	21.81
	8162205	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.4	CHEMBL5855	Homo sapiens	Inhibition	%	2.4
	8162365	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	1.41	CHEMBL5855	Homo sapiens	Inhibition	%	1.41
	8162589	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	0.88	CHEMBL5855	Homo sapiens	Inhibition	%	0.88
	8162618	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	1.89	CHEMBL5855	Homo sapiens	Inhibition	%	1.89
	8162842	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	3.47	CHEMBL5855	Homo sapiens	Inhibition	%	3.47
	8162990	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	3.02	CHEMBL5855	Homo sapiens	Inhibition	%	3.02
	8163159	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	0.65	CHEMBL5855	Homo sapiens	Inhibition	%	0.65
	8163383	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.19	CHEMBL5855	Homo sapiens	Inhibition	%	1.19
	8163517	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	4.01	CHEMBL5855	Homo sapiens	Inhibition	%	4.01
	8163864	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	3.2	CHEMBL5855	Homo sapiens	Inhibition	%	3.2
	8163998	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	3.63	CHEMBL5855	Homo sapiens	Inhibition	%	3.63
	8164222	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	21.64	CHEMBL5855	Homo sapiens	Inhibition	%	21.64
	8164362	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.9	CHEMBL5855	Homo sapiens	Inhibition	%	0.9
	8164517	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	6.07	CHEMBL5855	Homo sapiens	Inhibition	%	6.07
	8164741	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	2.07	CHEMBL5855	Homo sapiens	Inhibition	%	2.07
	8164885	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.03	CHEMBL5855	Homo sapiens	Inhibition	%	0.03
	8165179	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	0.87	CHEMBL5855	Homo sapiens	Inhibition	%	0.87
	8165544	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	1.65	CHEMBL5855	Homo sapiens	Inhibition	%	1.65
	8165687	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	20.38	CHEMBL5855	Homo sapiens	Inhibition	%	20.38
	8166037	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	2.01	CHEMBL5855	Homo sapiens	Inhibition	%	2.01
	8166175	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	1.79	CHEMBL5855	Homo sapiens	Inhibition	%	1.79
	8166399	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	3.87	CHEMBL5855	Homo sapiens	Inhibition	%	3.87
	8166529	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.81	CHEMBL5855	Homo sapiens	Inhibition	%	2.81
	8166854	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	7.77	CHEMBL5855	Homo sapiens	Inhibition	%	7.77
	8167166	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	1.53	CHEMBL5855	Homo sapiens	Inhibition	%	1.53
	8167307	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	6.96	CHEMBL5855	Homo sapiens	Inhibition	%	6.96
	8167695	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.42	CHEMBL5855	Homo sapiens	Inhibition	%	1.42
	8167828	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	3.29	CHEMBL5855	Homo sapiens	Inhibition	%	3.29
	8168052	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	4.51	CHEMBL5855	Homo sapiens	Inhibition	%	4.51
	8168176	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	2.09	CHEMBL5855	Homo sapiens	Inhibition	%	2.09
	8168541	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	2.6	CHEMBL5855	Homo sapiens	Inhibition	%	2.6
	8168677	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.83	CHEMBL5855	Homo sapiens	Inhibition	%	0.83
	8169065	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	10.94	CHEMBL5855	Homo sapiens	Inhibition	%	10.94
	8169207	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.54	CHEMBL5855	Homo sapiens	Inhibition	%	1.54
	8169431	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	-3.13	CHEMBL5855	Homo sapiens	Inhibition	%	-3.13
	8169511	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	2.58	CHEMBL5855	Homo sapiens	Inhibition	%	2.58
	8169869	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	3.04	CHEMBL5855	Homo sapiens	Inhibition	%	3.04
	8170014	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	1.24	CHEMBL5855	Homo sapiens	Inhibition	%	1.24
	8170238	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	6.51	CHEMBL5855	Homo sapiens	Inhibition	%	6.51
	8170363	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.0	CHEMBL5855	Homo sapiens	Inhibition	%	1.0
	8170727	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	2.19	CHEMBL5855	Homo sapiens	Inhibition	%	2.19
	8170862	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	3.39	CHEMBL5855	Homo sapiens	Inhibition	%	3.39
	8171283	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	1.89	CHEMBL5855	Homo sapiens	Inhibition	%	1.89
	8171500	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	3.94	CHEMBL5855	Homo sapiens	Inhibition	%	3.94
	8171641	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	2.74	CHEMBL5855	Homo sapiens	Inhibition	%	2.74
	8171865	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	2.8	CHEMBL5855	Homo sapiens	Inhibition	%	2.8
	8172018	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	2.19	CHEMBL5855	Homo sapiens	Inhibition	%	2.19
	8172374	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	2.99	CHEMBL5855	Homo sapiens	Inhibition	%	2.99
	8172502	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	4.56	CHEMBL5855	Homo sapiens	Inhibition	%	4.56
	8172868	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	3.93	CHEMBL5855	Homo sapiens	Inhibition	%	3.93
	8173004	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.9	CHEMBL5855	Homo sapiens	Inhibition	%	-0.9
	8173228	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.76	CHEMBL5855	Homo sapiens	Inhibition	%	-0.76
	8173393	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	3.6	CHEMBL5855	Homo sapiens	Inhibition	%	3.6
	8173758	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	2.32	CHEMBL5855	Homo sapiens	Inhibition	%	2.32
	8173845	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	2.19	CHEMBL5855	Homo sapiens	Inhibition	%	2.19
	8174069	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	-1.06	CHEMBL5855	Homo sapiens	Inhibition	%	-1.06
	8174201	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.51	CHEMBL5855	Homo sapiens	Inhibition	%	1.51
	8174573	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.66	CHEMBL5855	Homo sapiens	Inhibition	%	1.66
	8174695	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	3.8	CHEMBL5855	Homo sapiens	Inhibition	%	3.8
	8175062	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	3.24	CHEMBL5855	Homo sapiens	Inhibition	%	3.24
	8175198	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	3.1	CHEMBL5855	Homo sapiens	Inhibition	%	3.1
	8175422	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	13.53	CHEMBL5855	Homo sapiens	Inhibition	%	13.53
	8175678	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	5.21	CHEMBL5855	Homo sapiens	Inhibition	%	5.21
	8175841	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.28	CHEMBL5855	Homo sapiens	Inhibition	%	2.28
	8176218	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	3.18	CHEMBL5855	Homo sapiens	Inhibition	%	3.18
	8176367	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	1.87	CHEMBL5855	Homo sapiens	Inhibition	%	1.87
	8176723	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	2.85	CHEMBL5855	Homo sapiens	Inhibition	%	2.85
	8176853	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.35	CHEMBL5855	Homo sapiens	Inhibition	%	0.35
	8177077	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	2.46	CHEMBL5855	Homo sapiens	Inhibition	%	2.46
	8177219	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	3.13	CHEMBL5855	Homo sapiens	Inhibition	%	3.13
	8177581	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	0.76	CHEMBL5855	Homo sapiens	Inhibition	%	0.76
	8177745	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	12.5	CHEMBL5855	Homo sapiens	Inhibition	%	12.5
	8178109	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	0.46	CHEMBL5855	Homo sapiens	Inhibition	%	0.46
	8178421	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.2	CHEMBL5855	Homo sapiens	Inhibition	%	1.2
	8178548	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	3.23	CHEMBL5855	Homo sapiens	Inhibition	%	3.23
	8178921	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	2.92	CHEMBL5855	Homo sapiens	Inhibition	%	2.92
	8179044	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.8	CHEMBL5855	Homo sapiens	Inhibition	%	1.8
	8179268	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	2.36	CHEMBL5855	Homo sapiens	Inhibition	%	2.36
	8179412	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	1.96	CHEMBL5855	Homo sapiens	Inhibition	%	1.96
	8179773	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.4	CHEMBL5855	Homo sapiens	Inhibition	%	2.4
	8180030	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	2.01	CHEMBL5855	Homo sapiens	Inhibition	%	2.01
	8180184	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	3.95	CHEMBL5855	Homo sapiens	Inhibition	%	3.95
	8180564	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	3.48	CHEMBL5855	Homo sapiens	Inhibition	%	3.48
	8180712	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	1.42	CHEMBL5855	Homo sapiens	Inhibition	%	1.42
	8180936	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	2.38	CHEMBL5855	Homo sapiens	Inhibition	%	2.38
	8181069	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	2.87	CHEMBL5855	Homo sapiens	Inhibition	%	2.87
	8181424	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-0.12	CHEMBL5855	Homo sapiens	Inhibition	%	-0.12
	8181564	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	3.26	CHEMBL5855	Homo sapiens	Inhibition	%	3.26
	8181927	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	1.99	CHEMBL5855	Homo sapiens	Inhibition	%	1.99
	8182090	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	2.04	CHEMBL5855	Homo sapiens	Inhibition	%	2.04
	8182314	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	36.03	CHEMBL5855	Homo sapiens	Inhibition	%	36.03
	8182454	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.24	CHEMBL5855	Homo sapiens	Inhibition	%	1.24
	8182770	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	3.73	CHEMBL5855	Homo sapiens	Inhibition	%	3.73
	8182892	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	2.09	CHEMBL5855	Homo sapiens	Inhibition	%	2.09
	8183116	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	4.05	CHEMBL5855	Homo sapiens	Inhibition	%	4.05
	8183265	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.44	CHEMBL5855	Homo sapiens	Inhibition	%	0.44
	8183618	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	4.77	CHEMBL5855	Homo sapiens	Inhibition	%	4.77
	8183760	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	4.03	CHEMBL5855	Homo sapiens	Inhibition	%	4.03
	8183984	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	2.48	CHEMBL5855	Homo sapiens	Inhibition	%	2.48
	8184120	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.96	CHEMBL5855	Homo sapiens	Inhibition	%	2.96
	8184386	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	4.86	CHEMBL5855	Homo sapiens	Inhibition	%	4.86
	8184533	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.42	CHEMBL5855	Homo sapiens	Inhibition	%	1.42
	8184757	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	4.17	CHEMBL5855	Homo sapiens	Inhibition	%	4.17
	8184914	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	2.45	CHEMBL5855	Homo sapiens	Inhibition	%	2.45
	8185287	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.64	CHEMBL5855	Homo sapiens	Inhibition	%	0.64
	8185418	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	5.3	CHEMBL5855	Homo sapiens	Inhibition	%	5.3
	8185773	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	0.52	CHEMBL5855	Homo sapiens	Inhibition	%	0.52
	8185912	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.53	CHEMBL5855	Homo sapiens	Inhibition	%	1.53
	8186136	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	3.2	CHEMBL5855	Homo sapiens	Inhibition	%	3.2
	8186277	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.08	CHEMBL5855	Homo sapiens	Inhibition	%	1.08
	8186665	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	2.77	CHEMBL5855	Homo sapiens	Inhibition	%	2.77
	8186804	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.72	CHEMBL5855	Homo sapiens	Inhibition	%	1.72
	8187126	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.8	CHEMBL5855	Homo sapiens	Inhibition	%	1.8
	8187474	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	3.61	CHEMBL5855	Homo sapiens	Inhibition	%	3.61
	8187622	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	1.45	CHEMBL5855	Homo sapiens	Inhibition	%	1.45
	8187975	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	2.05	CHEMBL5855	Homo sapiens	Inhibition	%	2.05
	8188342	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	3.33	CHEMBL5855	Homo sapiens	Inhibition	%	3.33
	8188477	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.92	CHEMBL5855	Homo sapiens	Inhibition	%	1.92
	8188751	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.95	CHEMBL5855	Homo sapiens	Inhibition	%	3.95
	8189123	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	2.42	CHEMBL5855	Homo sapiens	Inhibition	%	2.42
	8189279	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	1.02	CHEMBL5855	Homo sapiens	Inhibition	%	1.02
	8189652	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	1.25	CHEMBL5855	Homo sapiens	Inhibition	%	1.25
	8189784	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	3.06	CHEMBL5855	Homo sapiens	Inhibition	%	3.06
	8190008	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	8.52	CHEMBL5855	Homo sapiens	Inhibition	%	8.52
	8190140	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	2.67	CHEMBL5855	Homo sapiens	Inhibition	%	2.67
	8190504	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	3.64	CHEMBL5855	Homo sapiens	Inhibition	%	3.64
	8190641	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	2.15	CHEMBL5855	Homo sapiens	Inhibition	%	2.15
	8190865	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	2.52	CHEMBL5855	Homo sapiens	Inhibition	%	2.52
	8191029	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	5.54	CHEMBL5855	Homo sapiens	Inhibition	%	5.54
	8191167	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	0.66	CHEMBL5855	Homo sapiens	Inhibition	%	0.66
	8191391	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	2.81	CHEMBL5855	Homo sapiens	Inhibition	%	2.81
	8191487	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	2.95	CHEMBL5855	Homo sapiens	Inhibition	%	2.95
	8191833	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	6.35	CHEMBL5855	Homo sapiens	Inhibition	%	6.35
	8191982	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.27	CHEMBL5855	Homo sapiens	Inhibition	%	1.27
	8192206	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.92	CHEMBL5855	Homo sapiens	Inhibition	%	1.92
	8192335	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	3.38	CHEMBL5855	Homo sapiens	Inhibition	%	3.38
	8192703	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	2.13	CHEMBL5855	Homo sapiens	Inhibition	%	2.13
	8192839	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	5.16	CHEMBL5855	Homo sapiens	Inhibition	%	5.16
	8193063	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	1.06	CHEMBL5855	Homo sapiens	Inhibition	%	1.06
	8193111	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.85	CHEMBL5855	Homo sapiens	Inhibition	%	4.85
	8193335	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.62	CHEMBL5855	Homo sapiens	Inhibition	%	1.62
	8193480	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	10.39	CHEMBL5855	Homo sapiens	Inhibition	%	10.39
	8193637	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	2.63	CHEMBL5855	Homo sapiens	Inhibition	%	2.63
	8193861	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	4.56	CHEMBL5855	Homo sapiens	Inhibition	%	4.56
	8194010	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.04	CHEMBL5855	Homo sapiens	Inhibition	%	-0.04
	8194365	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	3.4	CHEMBL5855	Homo sapiens	Inhibition	%	3.4
	8194496	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	0.39	CHEMBL5855	Homo sapiens	Inhibition	%	0.39
	8194720	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	3.18	CHEMBL5855	Homo sapiens	Inhibition	%	3.18
	8194863	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	3.27	CHEMBL5855	Homo sapiens	Inhibition	%	3.27
	8195220	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	3.44	CHEMBL5855	Homo sapiens	Inhibition	%	3.44
	8195384	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.66	CHEMBL5855	Homo sapiens	Inhibition	%	1.66
	8195747	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.17	CHEMBL5855	Homo sapiens	Inhibition	%	2.17
	8195845	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.75	CHEMBL5855	Homo sapiens	Inhibition	%	1.75
	8196069	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.45	CHEMBL5855	Homo sapiens	Inhibition	%	1.45
	8196186	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.8	CHEMBL5855	Homo sapiens	Inhibition	%	0.8
	8196560	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.02	CHEMBL5855	Homo sapiens	Inhibition	%	2.02
	8196688	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	1.51	CHEMBL5855	Homo sapiens	Inhibition	%	1.51
	8196912	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	3.32	CHEMBL5855	Homo sapiens	Inhibition	%	3.32
	8197053	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	4.28	CHEMBL5855	Homo sapiens	Inhibition	%	4.28
	8197414	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	2.42	CHEMBL5855	Homo sapiens	Inhibition	%	2.42
	8197689	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.03	CHEMBL5855	Homo sapiens	Inhibition	%	1.03
	8197829	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	3.45	CHEMBL5855	Homo sapiens	Inhibition	%	3.45
	8198210	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	2.77	CHEMBL5855	Homo sapiens	Inhibition	%	2.77
	8198348	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	0.27	CHEMBL5855	Homo sapiens	Inhibition	%	0.27
	8198572	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	2.81	CHEMBL5855	Homo sapiens	Inhibition	%	2.81
	8198702	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	5.46	CHEMBL5855	Homo sapiens	Inhibition	%	5.46
	8199057	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	2.69	CHEMBL5855	Homo sapiens	Inhibition	%	2.69
	8199205	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.45	CHEMBL5855	Homo sapiens	Inhibition	%	2.45
	8199563	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	3.31	CHEMBL5855	Homo sapiens	Inhibition	%	3.31
	8199726	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	6.79	CHEMBL5855	Homo sapiens	Inhibition	%	6.79
	8199950	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	2.47	CHEMBL5855	Homo sapiens	Inhibition	%	2.47
	8200088	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.95	CHEMBL5855	Homo sapiens	Inhibition	%	2.95
	8200416	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.79	CHEMBL5855	Homo sapiens	Inhibition	%	1.79
	8200531	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	6.65	CHEMBL5855	Homo sapiens	Inhibition	%	6.65
	8200755	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	3.25	CHEMBL5855	Homo sapiens	Inhibition	%	3.25
	8200905	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.14	CHEMBL5855	Homo sapiens	Inhibition	%	2.14
	8201259	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	7.88	CHEMBL5855	Homo sapiens	Inhibition	%	7.88
	8201394	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	2.31	CHEMBL5855	Homo sapiens	Inhibition	%	2.31
	8201751	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.36	CHEMBL5855	Homo sapiens	Inhibition	%	0.36
	8202030	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	2.28	CHEMBL5855	Homo sapiens	Inhibition	%	2.28
	8202170	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	15.49	CHEMBL5855	Homo sapiens	Inhibition	%	15.49
	8202394	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.4	CHEMBL5855	Homo sapiens	Inhibition	%	-0.4
	8202561	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	2.98	CHEMBL5855	Homo sapiens	Inhibition	%	2.98
	8202910	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	0.44	CHEMBL5855	Homo sapiens	Inhibition	%	0.44
	8203040	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	3.46	CHEMBL5855	Homo sapiens	Inhibition	%	3.46
	8203395	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	3.11	CHEMBL5855	Homo sapiens	Inhibition	%	3.11
	8203541	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	3.05	CHEMBL5855	Homo sapiens	Inhibition	%	3.05
	8203765	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.91	CHEMBL5855	Homo sapiens	Inhibition	%	1.91
	8203899	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	4.09	CHEMBL5855	Homo sapiens	Inhibition	%	4.09
	8204289	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	4.15	CHEMBL5855	Homo sapiens	Inhibition	%	4.15
	8204426	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.99	CHEMBL5855	Homo sapiens	Inhibition	%	2.99
	8204755	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.38	CHEMBL5855	Homo sapiens	Inhibition	%	1.38
	8205094	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	12.04	CHEMBL5855	Homo sapiens	Inhibition	%	12.04
	8205243	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	3.14	CHEMBL5855	Homo sapiens	Inhibition	%	3.14
	8205603	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	5.3	CHEMBL5855	Homo sapiens	Inhibition	%	5.3
	8205742	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	2.44	CHEMBL5855	Homo sapiens	Inhibition	%	2.44
	8205966	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.27	CHEMBL5855	Homo sapiens	Inhibition	%	2.27
	8206098	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.54	CHEMBL5855	Homo sapiens	Inhibition	%	0.54
	8206374	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	4.09	CHEMBL5855	Homo sapiens	Inhibition	%	4.09
	8206741	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	2.14	CHEMBL5855	Homo sapiens	Inhibition	%	2.14
	8206921	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	2.29	CHEMBL5855	Homo sapiens	Inhibition	%	2.29
	8207271	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.49	CHEMBL5855	Homo sapiens	Inhibition	%	2.49
	8207401	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	5.35	CHEMBL5855	Homo sapiens	Inhibition	%	5.35
	8207625	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	3.52	CHEMBL5855	Homo sapiens	Inhibition	%	3.52
	8207757	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	4.82	CHEMBL5855	Homo sapiens	Inhibition	%	4.82
	8208126	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	0.27	CHEMBL5855	Homo sapiens	Inhibition	%	0.27
	8208258	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	2.15	CHEMBL5855	Homo sapiens	Inhibition	%	2.15
	8208648	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	1.66	CHEMBL5855	Homo sapiens	Inhibition	%	1.66
	8208781	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.32	CHEMBL5855	Homo sapiens	Inhibition	%	2.32
	8209005	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.72	CHEMBL5855	Homo sapiens	Inhibition	%	1.72
	8209110	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.03	CHEMBL5855	Homo sapiens	Inhibition	%	1.03
	8209450	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.32	CHEMBL5855	Homo sapiens	Inhibition	%	2.32
	8209600	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	6.78	CHEMBL5855	Homo sapiens	Inhibition	%	6.78
	8209824	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.11	CHEMBL5855	Homo sapiens	Inhibition	%	1.11
	8209960	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	8.93	CHEMBL5855	Homo sapiens	Inhibition	%	8.93
	8210325	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	3.32	CHEMBL5855	Homo sapiens	Inhibition	%	3.32
	8210461	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-1.51	CHEMBL5855	Homo sapiens	Inhibition	%	-1.51
	8210720	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	2.48	CHEMBL5855	Homo sapiens	Inhibition	%	2.48
	8210944	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	4.54	CHEMBL5855	Homo sapiens	Inhibition	%	4.54
	8211088	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	2.43	CHEMBL5855	Homo sapiens	Inhibition	%	2.43
	8211258	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	2.28	CHEMBL5855	Homo sapiens	Inhibition	%	2.28
	8211482	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	2.94	CHEMBL5855	Homo sapiens	Inhibition	%	2.94
	8211605	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	6.68	CHEMBL5855	Homo sapiens	Inhibition	%	6.68
	8211958	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	11.22	CHEMBL5855	Homo sapiens	Inhibition	%	11.22
	8212090	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.64	CHEMBL5855	Homo sapiens	Inhibition	%	2.64
	8212455	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	2.65	CHEMBL5855	Homo sapiens	Inhibition	%	2.65
	8212588	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	3.74	CHEMBL5855	Homo sapiens	Inhibition	%	3.74
	8212812	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	3.27	CHEMBL5855	Homo sapiens	Inhibition	%	3.27
	8212982	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	2.46	CHEMBL5855	Homo sapiens	Inhibition	%	2.46
	8213335	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	6.39	CHEMBL5855	Homo sapiens	Inhibition	%	6.39
	8213439	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.67	CHEMBL5855	Homo sapiens	Inhibition	%	1.67
	8213663	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.84	CHEMBL5855	Homo sapiens	Inhibition	%	-0.84
	8213776	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	4.91	CHEMBL5855	Homo sapiens	Inhibition	%	4.91
	8214147	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.6	CHEMBL5855	Homo sapiens	Inhibition	%	1.6
	8214284	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	29.78	CHEMBL5855	Homo sapiens	Inhibition	%	29.78
	8214642	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	2.35	CHEMBL5855	Homo sapiens	Inhibition	%	2.35
	8214794	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.77	CHEMBL5855	Homo sapiens	Inhibition	%	0.77
	8215018	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	1.71	CHEMBL5855	Homo sapiens	Inhibition	%	1.71
	8215269	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	2.11	CHEMBL5855	Homo sapiens	Inhibition	%	2.11
	8215422	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	0.28	CHEMBL5855	Homo sapiens	Inhibition	%	0.28
	8215810	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.91	CHEMBL5855	Homo sapiens	Inhibition	%	1.91
	8215929	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	2.75	CHEMBL5855	Homo sapiens	Inhibition	%	2.75
	8216272	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	3.0	CHEMBL5855	Homo sapiens	Inhibition	%	3.0
	8216408	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.55	CHEMBL5855	Homo sapiens	Inhibition	%	2.55
	8216632	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	3.11	CHEMBL5855	Homo sapiens	Inhibition	%	3.11
	8216770	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	1.94	CHEMBL5855	Homo sapiens	Inhibition	%	1.94
	8217128	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	4.0	CHEMBL5855	Homo sapiens	Inhibition	%	4.0
	8217302	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.18	CHEMBL5855	Homo sapiens	Inhibition	%	0.18
	8217657	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	2.58	CHEMBL5855	Homo sapiens	Inhibition	%	2.58
	8217982	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-2.3	CHEMBL5855	Homo sapiens	Inhibition	%	-2.3
	8218097	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.81	CHEMBL5855	Homo sapiens	Inhibition	%	0.81
	8218448	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	2.06	CHEMBL5855	Homo sapiens	Inhibition	%	2.06
	8218591	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	67.79	CHEMBL5855	Homo sapiens	Inhibition	%	67.79
	8218815	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	5.73	CHEMBL5855	Homo sapiens	Inhibition	%	5.73
	8218946	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	3.58	CHEMBL5855	Homo sapiens	Inhibition	%	3.58
	8219330	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-2.23	CHEMBL5855	Homo sapiens	Inhibition	%	-2.23
	8219580	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	3.63	CHEMBL5855	Homo sapiens	Inhibition	%	3.63
	8219741	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.17	CHEMBL5855	Homo sapiens	Inhibition	%	2.17
	8220134	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.44	CHEMBL5855	Homo sapiens	Inhibition	%	2.44
	8220263	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	4.63	CHEMBL5855	Homo sapiens	Inhibition	%	4.63
	8220487	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	3.49	CHEMBL5855	Homo sapiens	Inhibition	%	3.49
	8220601	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	3.1	CHEMBL5855	Homo sapiens	Inhibition	%	3.1
	8220963	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	4.37	CHEMBL5855	Homo sapiens	Inhibition	%	4.37
	8221099	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.48	CHEMBL5855	Homo sapiens	Inhibition	%	1.48
	8221323	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	2.72	CHEMBL5855	Homo sapiens	Inhibition	%	2.72
	8221456	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	2.08	CHEMBL5855	Homo sapiens	Inhibition	%	2.08
	8221621	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	1.89	CHEMBL5855	Homo sapiens	Inhibition	%	1.89
	8221845	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.7	CHEMBL5855	Homo sapiens	Inhibition	%	-0.7
	8221976	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	3.0	CHEMBL5855	Homo sapiens	Inhibition	%	3.0
	8222298	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	1.59	CHEMBL5855	Homo sapiens	Inhibition	%	1.59
	8222432	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	5.31	CHEMBL5855	Homo sapiens	Inhibition	%	5.31
	8222656	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	2.41	CHEMBL5855	Homo sapiens	Inhibition	%	2.41
	8222774	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	7.24	CHEMBL5855	Homo sapiens	Inhibition	%	7.24
	8223142	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	16.89	CHEMBL5855	Homo sapiens	Inhibition	%	16.89
	8223271	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	1.92	CHEMBL5855	Homo sapiens	Inhibition	%	1.92
	8223495	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	2.89	CHEMBL5855	Homo sapiens	Inhibition	%	2.89
	8223656	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	1.41	CHEMBL5855	Homo sapiens	Inhibition	%	1.41
	8223906	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	3.37	CHEMBL5855	Homo sapiens	Inhibition	%	3.37
	8224068	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.92	CHEMBL5855	Homo sapiens	Inhibition	%	2.92
	8224292	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	2.74	CHEMBL5855	Homo sapiens	Inhibition	%	2.74
	8224462	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	3.22	CHEMBL5855	Homo sapiens	Inhibition	%	3.22
	8224821	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	4.61	CHEMBL5855	Homo sapiens	Inhibition	%	4.61
	8224935	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	2.99	CHEMBL5855	Homo sapiens	Inhibition	%	2.99
	8225159	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	3.61	CHEMBL5855	Homo sapiens	Inhibition	%	3.61
	8225293	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	3.72	CHEMBL5855	Homo sapiens	Inhibition	%	3.72
	8225655	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	2.25	CHEMBL5855	Homo sapiens	Inhibition	%	2.25
	8225790	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	5.01	CHEMBL5855	Homo sapiens	Inhibition	%	5.01
	8226172	CHEMBL1962087	GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.29	CHEMBL5855	Homo sapiens	Inhibition	%	1.29
	8226297	CHEMBL1962086	GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.09	CHEMBL5855	Homo sapiens	Inhibition	%	2.09
	10839420	CHEMBL2015082	Inhibition of NEK1 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	5.0	CHEMBL5855	Homo sapiens	INH	%	5.0
	12047279	CHEMBL2157304	Inhibition of NEK1 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	1.3	CHEMBL5855	Homo sapiens	INH	%	1.3
	12172320	CHEMBL2215435	Inhibition of NEK1 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	99.0	CHEMBL5855	Homo sapiens	Activity	%	99.0
	12626699	CHEMBL2316977	Inhibition of NEK1 (unknown origin) at 1 uM	B	COc1cc(Nc2ncc(Cl)c(-c3cccc(CC#N)c3)n2)ccc1N1CCN(C)CC1		CHEMBL2312140	>=	Inhibition	%	80.0	CHEMBL5855	Homo sapiens	INH	%	80.0
	12700053	CHEMBL2344115	Inhibition of recombinant NEK1 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)[C@@H](Cc2ccccn2)C1		CHEMBL2338335	=	IC50	nM	83000.0	CHEMBL5855	Homo sapiens	IC50	uM	83.0
	12700065	CHEMBL2344115	Inhibition of recombinant NEK1 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)[C@H](Cc2ccccn2)C1		CHEMBL2338334	=	IC50	nM	83000.0	CHEMBL5855	Homo sapiens	IC50	uM	83.0
	12700077	CHEMBL2344115	Inhibition of recombinant NEK1 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CSC/C1=C\c1ccccn1		CHEMBL2036343	=	IC50	nM	14000.0	CHEMBL5855	Homo sapiens	IC50	uM	14.0
	12700089	CHEMBL2344115	Inhibition of recombinant NEK1 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)/C(=C/c2ccccn2)C1		CHEMBL2338333	=	IC50	nM	3500.0	CHEMBL5855	Homo sapiens	IC50	uM	3.5
	12700102	CHEMBL2344115	Inhibition of recombinant NEK1 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	IC50	nM	500.0	CHEMBL5855	Homo sapiens	IC50	uM	0.5
	12700157	CHEMBL2342695	Inhibition of recombinant NEK1 (unknown origin) at 5 uM by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	Inhibition	%	102.0	CHEMBL5855	Homo sapiens	INH	%	102.0
	12700164	CHEMBL2344115	Inhibition of recombinant NEK1 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccc2F)CNC/C1=C\c1ccccc1F		CHEMBL379849	=	IC50	nM	77000.0	CHEMBL5855	Homo sapiens	IC50	uM	77.0
	12727713	CHEMBL2351147	Inhibition of NEK1 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	90.0	CHEMBL5855	Homo sapiens	Activity	%	90.0
	12729001	CHEMBL2350178	Inhibition of NEK1 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	95.0	CHEMBL5855	Homo sapiens	Activity	%	95.0
	12729888	CHEMBL2349792	Inhibition of NEK1 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	87.0	CHEMBL5855	Homo sapiens	Activity	%	87.0
	12730144	CHEMBL2351147	Inhibition of NEK1 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	92.0	CHEMBL5855	Homo sapiens	Activity	%	92.0
	13374426	CHEMBL2404162	Inhibition of NEK1 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	-1.0	CHEMBL5855	Homo sapiens	INH	%	-1.0
	13439793	CHEMBL2429145	Competitive binding affinity to NEK1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	=	Inhibition	%	84.0	CHEMBL5855	Homo sapiens	INH	%	84.0
	13442415	CHEMBL2429145	Competitive binding affinity to NEK1 (unknown origin) at 10 uM in presence of ATP relative to control	B	CS(=O)(=O)CCCOc1cccc2c1ccn2-c1ccnc(N[C@H]2CC[C@H](C(=O)N3CCC(O)CC3)CC2)n1		CHEMBL2425628	>	Inhibition	%	85.0	CHEMBL5855	Homo sapiens	INH	%	85.0
	13442484	CHEMBL2429178	Binding affinity to NEK1 (unknown origin)	B	CS(=O)(=O)CCCOc1cccc2c1ccn2-c1ccnc(N[C@H]2CC[C@H](C(=O)N3CCC(O)CC3)CC2)n1		CHEMBL2425628	=	Kd	nM	4000.0	CHEMBL5855	Homo sapiens	Kd	uM	4.0
	13445626	CHEMBL2429145	Competitive binding affinity to NEK1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	=	Inhibition	%	96.0	CHEMBL5855	Homo sapiens	INH	%	96.0
	13451613	CHEMBL2429145	Competitive binding affinity to NEK1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	=	Inhibition	%	98.0	CHEMBL5855	Homo sapiens	INH	%	98.0
	14593763	CHEMBL3241180	Inhibition of human NEK1	B	Oc1cccc(Nc2ccnc3[nH]c4ccccc4c23)c1		CHEMBL3133821	>	IC50	nM	10000.0	CHEMBL5855	Homo sapiens	IC50	uM	10.0
	14983180	CHEMBL3385019	Inhibition of NEK1 (unknown origin) at 1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	9.0	CHEMBL5855	Homo sapiens	INH	%	9.0
	14984422	CHEMBL3384369	Inhibition of NEK1 (unknown origin) at 0.1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	-9.0	CHEMBL5855	Homo sapiens	INH	%	-9.0
	14992858	CHEMBL3372231	Inhibition of recombinant NEK1 (unknown origin) after 60 mins by z'-lyte kinase assay	B	O=C1/C(=C\c2ccc(O)c(O)c2)Oc2ccccc21		CHEMBL3361128	=	IC50	nM	11500.0	CHEMBL5855	Homo sapiens	IC50	uM	11.5
	15018650	CHEMBL3361542	Inhibition of NEK1 (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	2.9	CHEMBL5855	Homo sapiens	INH	%	2.9
	15650151	CHEMBL3595417	Inhibition of human NEK1 at 0.1 uM relative to control	B	CCc1cc(NC(=O)Nc2ccc(-c3cnc(Nc4cc(N5CCN(CC)CC5)nc(C)n4)s3)cc2)no1		CHEMBL3593290	=	Inhibition	%	23.0	CHEMBL5855	Homo sapiens	INH	%	23.0
	15754254	CHEMBL3631179	Inhibition of NEK1 (unknown origin) at 1 uM by FRET method	B	N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)n(C3CCCC3)n2)c1		CHEMBL3629013	=	Inhibition	%	3.1	CHEMBL5855	Homo sapiens	INH	%	3.1
	15756893	CHEMBL3631463	Inhibition of NEK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	12.46	CHEMBL5855	Homo sapiens	INH	%	12.46
	15757830	CHEMBL3631463	Inhibition of NEK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	15.41	CHEMBL5855	Homo sapiens	INH	%	15.41
	15758809	CHEMBL3631463	Inhibition of NEK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	2.5	CHEMBL5855	Homo sapiens	INH	%	2.5
273896	16285217	CHEMBL3707978	Kinase Inhibition Assay: The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase inhibition assay for the kinases. Compounds were tested in 5 dose IC50 mode with 10-fold serial dilution starting at 10 M. Staurosporine, a known protein kinase inhibitor, was tested in 5-dose IC50 mode with 3-fold serial dilution starting at 20 M. Reactions were carried out in 10 M ATP. The results are shown in Table 5. The results show that the compound of Example 39 is a kinase inhibitor highly selective for the kinase Plk2.	B	CN[C@H]1CC2OC([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(O)=NC4		CHEMBL3975634	=	IC50	nM	432.6	CHEMBL5855	Homo sapiens	IC50	nM	432.6
273895	16315891	CHEMBL3707978	Kinase Inhibition Assay: The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase inhibition assay for the kinases. Compounds were tested in 5 dose IC50 mode with 10-fold serial dilution starting at 10 M. Staurosporine, a known protein kinase inhibitor, was tested in 5-dose IC50 mode with 3-fold serial dilution starting at 20 M. Reactions were carried out in 10 M ATP. The results are shown in Table 5. The results show that the compound of Example 39 is a kinase inhibitor highly selective for the kinase Plk2.	B	CN[C@H]1CC2OC([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(O)=NC4		CHEMBL3975634	=	IC50	nM	150.4	CHEMBL5855	Homo sapiens	IC50	nM	150.4
273863	16323459	CHEMBL3707978	Kinase Inhibition Assay: The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase inhibition assay for the kinases. Compounds were tested in 5 dose IC50 mode with 10-fold serial dilution starting at 10 M. Staurosporine, a known protein kinase inhibitor, was tested in 5-dose IC50 mode with 3-fold serial dilution starting at 20 M. Reactions were carried out in 10 M ATP. The results are shown in Table 5. The results show that the compound of Example 39 is a kinase inhibitor highly selective for the kinase Plk2.	B	Cn1c(=O)c(Sc2ccc(F)cc2)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3702566	>	IC50	nM	10000.0	CHEMBL5855	Homo sapiens	IC50	nM	10000.0
273864	16328816	CHEMBL3707978	Kinase Inhibition Assay: The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase inhibition assay for the kinases. Compounds were tested in 5 dose IC50 mode with 10-fold serial dilution starting at 10 M. Staurosporine, a known protein kinase inhibitor, was tested in 5-dose IC50 mode with 3-fold serial dilution starting at 20 M. Reactions were carried out in 10 M ATP. The results are shown in Table 5. The results show that the compound of Example 39 is a kinase inhibitor highly selective for the kinase Plk2.	B	Cn1c(=O)c(Sc2ccc(F)cc2)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3702566	>	IC50	nM	10000.0	CHEMBL5855	Homo sapiens	IC50	nM	10000.0
	16425403	CHEMBL3751050	Inhibition of NEK1 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	1.5	CHEMBL5855	Homo sapiens	INH	%	1.5
	16431925	CHEMBL3748018	Inhibition of human NEK1 using MBP as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	=	IC50	nM	630.0	CHEMBL5855	Homo sapiens	IC50	uM	0.63
	16451537	CHEMBL3760660	Inhibition of NEK1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	6.8	CHEMBL5855	Homo sapiens	INH	%	6.8
	16451741	CHEMBL3760660	Inhibition of NEK1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758602	=	Inhibition	%	-4.0	CHEMBL5855	Homo sapiens	INH	%	-4.0
	16458526	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	C[C@@H](Nc1ncnc2sc(-c3ccccc3C(N)=O)cc12)c1ccccc1		CHEMBL3759085	=	Inhibition	%	3.0	CHEMBL5855	Homo sapiens	INH	%	3.0
	16458527	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	C[C@@H](Nc1ncnc2sc(-c3ccc(C(=O)NCCN(C)C)cc3)cc12)c1ccccc1		CHEMBL3758800	=	Inhibition	%	4.0	CHEMBL5855	Homo sapiens	INH	%	4.0
	16458528	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	CN(C)CCNC(=O)c1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3s2)cc1	Outside typical range	CHEMBL3758376	=	Inhibition	%	-11.0	CHEMBL5855	Homo sapiens	INH	%	-11.0
	16458529	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1		CHEMBL3759480	=	Inhibition	%	3.0	CHEMBL5855	Homo sapiens	INH	%	3.0
	16458530	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	COc1ccc(C(=O)NCCN(C)C)cc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1		CHEMBL3758582	=	Inhibition	%	-4.0	CHEMBL5855	Homo sapiens	INH	%	-4.0
	16458531	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1		CHEMBL3759559	=	Inhibition	%	1.0	CHEMBL5855	Homo sapiens	INH	%	1.0
	16458532	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1		CHEMBL3758682	=	Inhibition	%	13.0	CHEMBL5855	Homo sapiens	INH	%	13.0
	16458533	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(Nc3ccccc3)ncnc2s1		CHEMBL3758768	=	Inhibition	%	-5.0	CHEMBL5855	Homo sapiens	INH	%	-5.0
	16458534	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	C#Cc1cccc(Nc2ncnc3sc(-c4ccc(CO)cc4OC)cc23)c1		CHEMBL3758802	=	Inhibition	%	-6.0	CHEMBL5855	Homo sapiens	INH	%	-6.0
	16458535	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1	Outside typical range	CHEMBL3758351	=	Inhibition	%	-11.0	CHEMBL5855	Homo sapiens	INH	%	-11.0
	16458536	CHEMBL3761592	Inhibition of NEK1 (unknown origin) at 500 nM	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-8.0	CHEMBL5855	Homo sapiens	INH	%	-8.0
	16614557	CHEMBL3817588	Inhibition of human NEK1 at 1 uM using MBP as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	16618148	CHEMBL3817269	Inhibition of recombinant human GST-tagged NEK1 catalytic domain (1 to 505 residues) expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	16739427	CHEMBL3857067	Inhibition of GST tagged recombinant human NEK1 catalytic domain (1 to 505 residues) expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN(C)C)cc3)cc12)c1ccccc1		CHEMBL3901622	=	Inhibition	%	3.0	CHEMBL5855	Homo sapiens	INH	%	3.0
	16739428	CHEMBL3857067	Inhibition of GST tagged recombinant human NEK1 catalytic domain (1 to 505 residues) expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN4CCCCC4)cc3)cc12)c1ccccc1		CHEMBL3891846	=	Inhibition	%	-1.0	CHEMBL5855	Homo sapiens	INH	%	-1.0
	16739429	CHEMBL3857067	Inhibition of GST tagged recombinant human NEK1 catalytic domain (1 to 505 residues) expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-8.0	CHEMBL5855	Homo sapiens	INH	%	-8.0
287382	17669727	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N[C@H]1CCN(c2ccc3[nH]c(=O)c4sc(-c5ccc(O)cc5)cc4c3c2)C1		CHEMBL3667201	=	IC50	nM	78.0	CHEMBL5855	Homo sapiens	IC50	nM	78.0
287383	17669728	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(-c3ccc4cn[nH]c4c3)c2c2ccsc12		CHEMBL3667202	=	IC50	nM	3.5	CHEMBL5855	Homo sapiens	IC50	nM	3.5
287384	17669729	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NS(=O)(=O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667203	=	IC50	nM	1.8	CHEMBL5855	Homo sapiens	IC50	nM	1.8
287385	17669730	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667204	=	IC50	nM	0.63	CHEMBL5855	Homo sapiens	IC50	nM	0.63
287386	17669731	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667204	=	IC50	nM	0.38	CHEMBL5855	Homo sapiens	IC50	nM	0.38
287387	17669732	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)Nc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667205	=	IC50	nM	2.6	CHEMBL5855	Homo sapiens	IC50	nM	2.6
287388	17669733	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#CCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667206	=	IC50	nM	12.0	CHEMBL5855	Homo sapiens	IC50	nM	12.0
287389	17669734	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(C3=CCNCC3)c2c2ccsc12		CHEMBL3667207	=	IC50	nM	0.78	CHEMBL5855	Homo sapiens	IC50	nM	0.78
287390	17669735	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667208	=	IC50	nM	5.4	CHEMBL5855	Homo sapiens	IC50	nM	5.4
287391	17669736	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc2c(s1)c(=O)[nH]c1ccc(O)c(-c3ccc(CN)cc3)c12		CHEMBL3667209	=	IC50	nM	4.4	CHEMBL5855	Homo sapiens	IC50	nM	4.4
287392	17669737	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)N1CCN(c2ccc(-c3c(O)ccc4[nH]c(=O)c5sccc5c34)cc2)CC1		CHEMBL3667210	=	IC50	nM	12.0	CHEMBL5855	Homo sapiens	IC50	nM	12.0
287393	17669738	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(CN2CCC(CNC(=O)OC(C)(C)C)CC2)cc1		CHEMBL3667211	=	IC50	nM	9.4	CHEMBL5855	Homo sapiens	IC50	nM	9.4
287394	17669739	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)CCNCCCOc1ccc(-c2c(OC)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667212	=	IC50	nM	47.0	CHEMBL5855	Homo sapiens	IC50	nM	47.0
287395	17669740	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1/C=C/CN1CCC(N)CC1		CHEMBL3667213	=	IC50	nM	31.0	CHEMBL5855	Homo sapiens	IC50	nM	31.0
287396	17669741	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(CN(C)C)cc1		CHEMBL3667214	=	IC50	nM	11.0	CHEMBL5855	Homo sapiens	IC50	nM	11.0
287397	17669742	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)Cc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667215	=	IC50	nM	6.9	CHEMBL5855	Homo sapiens	IC50	nM	6.9
287398	17669743	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(CCN)cc1		CHEMBL3667216	=	IC50	nM	22.0	CHEMBL5855	Homo sapiens	IC50	nM	22.0
287399	17669744	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667217	=	IC50	nM	1.2	CHEMBL5855	Homo sapiens	IC50	nM	1.2
287400	17669745	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667217	=	IC50	nM	1.1	CHEMBL5855	Homo sapiens	IC50	nM	1.1
287401	17669746	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)Cc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667218	=	IC50	nM	7.7	CHEMBL5855	Homo sapiens	IC50	nM	7.7
287402	17669747	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667219	=	IC50	nM	0.9	CHEMBL5855	Homo sapiens	IC50	nM	0.9
287403	17669748	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCc1ccc(-c2c(OC)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667220	=	IC50	nM	7.8	CHEMBL5855	Homo sapiens	IC50	nM	7.8
287404	17669749	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3667221	=	IC50	nM	1.6	CHEMBL5855	Homo sapiens	IC50	nM	1.6
287405	17669750	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3667221	=	IC50	nM	1.9	CHEMBL5855	Homo sapiens	IC50	nM	1.9
287406	17669751	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(NS(C)(=O)=O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667222	=	IC50	nM	3.7	CHEMBL5855	Homo sapiens	IC50	nM	3.7
287407	17669752	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N1CCCC1		CHEMBL3667223	=	IC50	nM	2.8	CHEMBL5855	Homo sapiens	IC50	nM	2.8
287408	17669753	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667224	=	IC50	nM	0.73	CHEMBL5855	Homo sapiens	IC50	nM	0.73
287409	17669754	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C(C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667225	=	IC50	nM	4.5	CHEMBL5855	Homo sapiens	IC50	nM	4.5
287410	17669755	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(-c3ccc(S(=O)(=O)NCCBr)cc3)c2c2ccsc12		CHEMBL3667226	=	IC50	nM	11.3	CHEMBL5855	Homo sapiens	IC50	nM	11.3
287411	17669756	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CS(=O)(=O)NCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667227	=	IC50	nM	5.5	CHEMBL5855	Homo sapiens	IC50	nM	5.5
287412	17669757	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(C(C)N2CCCC2)cc1		CHEMBL3667228	=	IC50	nM	21.0	CHEMBL5855	Homo sapiens	IC50	nM	21.0
287413	17669758	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Nc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1O		CHEMBL3667229	=	IC50	nM	2.3	CHEMBL5855	Homo sapiens	IC50	nM	2.3
287414	17669759	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(F)c2[nH]c(=O)c3sccc3c2c1-c1ccc(CCN(C)C)cc1		CHEMBL3667230	=	IC50	nM	82.0	CHEMBL5855	Homo sapiens	IC50	nM	82.0
287415	17669760	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(c1ccc(-c2c(O)cc(F)c3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3667231	=	IC50	nM	23.0	CHEMBL5855	Homo sapiens	IC50	nM	23.0
287416	17669761	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)NCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3639660	=	IC50	nM	4.2	CHEMBL5855	Homo sapiens	IC50	nM	4.2
287417	17669762	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc([C@H](C)N)cc1		CHEMBL3667232	=	IC50	nM	7.4	CHEMBL5855	Homo sapiens	IC50	nM	7.4
287418	17669763	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@H](N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667233	=	IC50	nM	0.81	CHEMBL5855	Homo sapiens	IC50	nM	0.81
287419	17669764	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCC1CCN(Cc2ccc(-c3c(O)ccc4[nH]c(=O)c5sccc5c34)cc2F)CC1		CHEMBL3667234	=	IC50	nM	0.57	CHEMBL5855	Homo sapiens	IC50	nM	0.57
287420	17669765	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)ccc1NS(C)(=O)=O		CHEMBL3667235	=	IC50	nM	3.0	CHEMBL5855	Homo sapiens	IC50	nM	3.0
287421	17669766	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(-c2c(O)cc(F)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667236	=	IC50	nM	2.5	CHEMBL5855	Homo sapiens	IC50	nM	2.5
287422	17669767	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(F)c2[nH]c(=O)c3sccc3c2c1-c1ccc(CN)cc1		CHEMBL3667237	=	IC50	nM	26.0	CHEMBL5855	Homo sapiens	IC50	nM	26.0
287423	17669768	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#CCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3667238	=	IC50	nM	15.0	CHEMBL5855	Homo sapiens	IC50	nM	15.0
287424	17669769	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N1CCCCC1		CHEMBL3667239	=	IC50	nM	4.3	CHEMBL5855	Homo sapiens	IC50	nM	4.3
287425	17669770	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(CCN)c(F)c1		CHEMBL3667240	=	IC50	nM	3.8	CHEMBL5855	Homo sapiens	IC50	nM	3.8
287426	17669771	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)s1		CHEMBL3667241	=	IC50	nM	0.78	CHEMBL5855	Homo sapiens	IC50	nM	0.78
287427	17669772	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCNCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667242	=	IC50	nM	2.0	CHEMBL5855	Homo sapiens	IC50	nM	2.0
287428	17669773	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCNCc1ccc(-c2c(OC)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667243	=	IC50	nM	6.0	CHEMBL5855	Homo sapiens	IC50	nM	6.0
287429	17669774	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667244	=	IC50	nM	31.0	CHEMBL5855	Homo sapiens	IC50	nM	31.0
287430	17669775	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@H](c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3667245	=	IC50	nM	0.88	CHEMBL5855	Homo sapiens	IC50	nM	0.88
287431	17669776	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667246	=	IC50	nM	0.74	CHEMBL5855	Homo sapiens	IC50	nM	0.74
287432	17669777	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc([C@@H](C)N)cc1		CHEMBL3667247	=	IC50	nM	3.8	CHEMBL5855	Homo sapiens	IC50	nM	3.8
287433	17669778	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667248	=	IC50	nM	0.54	CHEMBL5855	Homo sapiens	IC50	nM	0.54
287434	17669779	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3667249	=	IC50	nM	0.5	CHEMBL5855	Homo sapiens	IC50	nM	0.5
287435	17669780	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667250	=	IC50	nM	0.67	CHEMBL5855	Homo sapiens	IC50	nM	0.67
287436	17669781	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(-c3ccc(CN4CCC(O)C4)c(F)c3)c2c2ccsc12		CHEMBL3667251	=	IC50	nM	0.97	CHEMBL5855	Homo sapiens	IC50	nM	0.97
287437	17669782	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#CCCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667252	=	IC50	nM	3.2	CHEMBL5855	Homo sapiens	IC50	nM	3.2
287438	17669783	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667253	=	IC50	nM	23.0	CHEMBL5855	Homo sapiens	IC50	nM	23.0
287439	17669784	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(-c3ccc(S(=O)(=O)NCCBr)c(F)c3)c2c2ccsc12		CHEMBL3667254	=	IC50	nM	13.0	CHEMBL5855	Homo sapiens	IC50	nM	13.0
287440	17669785	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)C1CCCN(CCCc2c(O)ccc3[nH]c(=O)c4sccc4c23)C1		CHEMBL3667255	=	IC50	nM	83.0	CHEMBL5855	Homo sapiens	IC50	nM	83.0
287441	17669786	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](NS(C)(=O)=O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667256	=	IC50	nM	3.2	CHEMBL5855	Homo sapiens	IC50	nM	3.2
287442	17669787	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)S(=O)(=O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667257	=	IC50	nM	45.0	CHEMBL5855	Homo sapiens	IC50	nM	45.0
287443	17669788	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC(C)(C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667258	=	IC50	nM	2.8	CHEMBL5855	Homo sapiens	IC50	nM	2.8
287444	17669789	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667259	=	IC50	nM	2.0	CHEMBL5855	Homo sapiens	IC50	nM	2.0
287445	17669790	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(NC1CCCC1)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667260	=	IC50	nM	2.8	CHEMBL5855	Homo sapiens	IC50	nM	2.8
287446	17669791	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667261	=	IC50	nM	0.43	CHEMBL5855	Homo sapiens	IC50	nM	0.43
287447	17669792	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#Cc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(CN)cc1		CHEMBL3667262	=	IC50	nM	13.0	CHEMBL5855	Homo sapiens	IC50	nM	13.0
287448	17669793	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CCc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3667263	=	IC50	nM	1.9	CHEMBL5855	Homo sapiens	IC50	nM	1.9
287449	17669794	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCc1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667264	=	IC50	nM	16.0	CHEMBL5855	Homo sapiens	IC50	nM	16.0
287450	17669795	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(-c3ccc(S(=O)(=O)NCCCl)cc3)c2c2ccsc12		CHEMBL3672231	=	IC50	nM	23.0	CHEMBL5855	Homo sapiens	IC50	nM	23.0
287451	17669796	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(S(=O)(=O)NCCF)cc1		CHEMBL3672232	=	IC50	nM	31.0	CHEMBL5855	Homo sapiens	IC50	nM	31.0
287452	17669797	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(N)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672233	=	IC50	nM	10.0	CHEMBL5855	Homo sapiens	IC50	nM	10.0
287453	17669798	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3672234	=	IC50	nM	2.9	CHEMBL5855	Homo sapiens	IC50	nM	2.9
287454	17669799	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672235	=	IC50	nM	0.82	CHEMBL5855	Homo sapiens	IC50	nM	0.82
287455	17669800	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(N)c1ccc(-c2c(OC)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672236	=	IC50	nM	5.2	CHEMBL5855	Homo sapiens	IC50	nM	5.2
287456	17669801	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N(CC)CC		CHEMBL3672237	=	IC50	nM	3.7	CHEMBL5855	Homo sapiens	IC50	nM	3.7
287457	17669802	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3672238	=	IC50	nM	1.9	CHEMBL5855	Homo sapiens	IC50	nM	1.9
287458	17669803	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(c1ccc(-c2c(O)c(F)c(F)c3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3672239	=	IC50	nM	34.0	CHEMBL5855	Homo sapiens	IC50	nM	34.0
287459	17669804	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NC1Cc2ccc(-c3c(O)ccc4[nH]c(=O)c5sccc5c34)cc2C1		CHEMBL3672240	=	IC50	nM	1.2	CHEMBL5855	Homo sapiens	IC50	nM	1.2
287460	17669805	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(c1ccc(-c2cccc3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3672241	=	IC50	nM	9.2	CHEMBL5855	Homo sapiens	IC50	nM	9.2
287461	17669806	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(NS(C)(=O)=O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3667222	=	IC50	nM	2.0	CHEMBL5855	Homo sapiens	IC50	nM	2.0
287462	17669807	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCC1(c2ccc(-c3c(O)ccc4[nH]c(=O)c5sccc5c34)cc2)CC1		CHEMBL3672242	=	IC50	nM	1.9	CHEMBL5855	Homo sapiens	IC50	nM	1.9
287463	17669808	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1F)N(C)C		CHEMBL3672243	=	IC50	nM	1.9	CHEMBL5855	Homo sapiens	IC50	nM	1.9
287464	17669809	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(-c3ccc4c(c3)CNCC4)c2c2ccsc12		CHEMBL3672244	=	IC50	nM	2.0	CHEMBL5855	Homo sapiens	IC50	nM	2.0
287465	17669810	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(CC)C(C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672245	=	IC50	nM	3.6	CHEMBL5855	Homo sapiens	IC50	nM	3.6
287466	17669811	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672246	=	IC50	nM	0.92	CHEMBL5855	Homo sapiens	IC50	nM	0.92
287467	17669812	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	N#CC1(c2ccc(-c3c(O)ccc4[nH]c(=O)c5sccc5c34)cc2)CC1		CHEMBL3672247	=	IC50	nM	32.0	CHEMBL5855	Homo sapiens	IC50	nM	32.0
287468	17669813	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(C(C)CN)cc1		CHEMBL3672248	=	IC50	nM	3.2	CHEMBL5855	Homo sapiens	IC50	nM	3.2
287469	17669814	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN(C)CC1(c2ccc(-c3c(O)ccc4[nH]c(=O)c5sccc5c34)cc2)CC1		CHEMBL3672249	=	IC50	nM	3.6	CHEMBL5855	Homo sapiens	IC50	nM	3.6
287470	17669815	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCNC(C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672250	=	IC50	nM	3.9	CHEMBL5855	Homo sapiens	IC50	nM	3.9
287471	17669816	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(N)c1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672251	=	IC50	nM	47.0	CHEMBL5855	Homo sapiens	IC50	nM	47.0
287472	17669817	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(N)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672252	=	IC50	nM	12.0	CHEMBL5855	Homo sapiens	IC50	nM	12.0
287473	17669818	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H](C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672253	=	IC50	nM	1.3	CHEMBL5855	Homo sapiens	IC50	nM	1.3
287474	17669819	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(CBr)NS(=O)(=O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672254	=	IC50	nM	31.0	CHEMBL5855	Homo sapiens	IC50	nM	31.0
287475	17669820	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@@H](C)c1ccc(-c2c(OC)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672255	=	IC50	nM	2.5	CHEMBL5855	Homo sapiens	IC50	nM	2.5
287476	17669821	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(C)N)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672256	=	IC50	nM	12.0	CHEMBL5855	Homo sapiens	IC50	nM	12.0
287477	17669822	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)OC(=O)Oc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(C(C)N)cc1		CHEMBL3672257	=	IC50	nM	76.0	CHEMBL5855	Homo sapiens	IC50	nM	76.0
287478	17669823	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](N)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672258	=	IC50	nM	8.6	CHEMBL5855	Homo sapiens	IC50	nM	8.6
287479	17669824	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@@H](C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672259	=	IC50	nM	1.1	CHEMBL5855	Homo sapiens	IC50	nM	1.1
287480	17669825	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@@H](C)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672260	=	IC50	nM	19.0	CHEMBL5855	Homo sapiens	IC50	nM	19.0
287481	17669826	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(N)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672261	=	IC50	nM	16.0	CHEMBL5855	Homo sapiens	IC50	nM	16.0
287482	17669827	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(-c3ccc(S(=O)(=O)NCCBr)cc3)c2c2c1CCC2		CHEMBL3672262	=	IC50	nM	10.0	CHEMBL5855	Homo sapiens	IC50	nM	10.0
287483	17669828	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(N)Cc1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672263	=	IC50	nM	1.3	CHEMBL5855	Homo sapiens	IC50	nM	1.3
287484	17669829	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(=O)Oc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(C(C)N)cc1		CHEMBL3672264	=	IC50	nM	33.0	CHEMBL5855	Homo sapiens	IC50	nM	33.0
287485	17669830	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(N)Cc1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672265	=	IC50	nM	41.0	CHEMBL5855	Homo sapiens	IC50	nM	41.0
287486	17669831	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672266	=	IC50	nM	1.3	CHEMBL5855	Homo sapiens	IC50	nM	1.3
287487	17669832	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(CN(C)C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672267	=	IC50	nM	3.3	CHEMBL5855	Homo sapiens	IC50	nM	3.3
287488	17669833	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCC1(c2ccc(-c3c(O)cc(Cl)c4[nH]c(=O)c5sccc5c34)cc2)CC1		CHEMBL3672268	=	IC50	nM	22.0	CHEMBL5855	Homo sapiens	IC50	nM	22.0
287489	17669834	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@H](N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672269	=	IC50	nM	0.88	CHEMBL5855	Homo sapiens	IC50	nM	0.88
287490	17669835	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@H](N)c1ccc(-c2c(OC)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672270	=	IC50	nM	2.9	CHEMBL5855	Homo sapiens	IC50	nM	2.9
287491	17669836	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)N)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672271	=	IC50	nM	5.9	CHEMBL5855	Homo sapiens	IC50	nM	5.9
287492	17669837	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](N)c1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672272	=	IC50	nM	33.0	CHEMBL5855	Homo sapiens	IC50	nM	33.0
287493	17669838	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@H](c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3672273	=	IC50	nM	42.0	CHEMBL5855	Homo sapiens	IC50	nM	42.0
287494	17669839	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN[C@H](CC)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672274	=	IC50	nM	1.4	CHEMBL5855	Homo sapiens	IC50	nM	1.4
287495	17669840	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@@H](c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3672275	=	IC50	nM	2.2	CHEMBL5855	Homo sapiens	IC50	nM	2.2
287496	17669841	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@@H](N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672276	=	IC50	nM	1.3	CHEMBL5855	Homo sapiens	IC50	nM	1.3
287497	17669842	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H](C)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672277	=	IC50	nM	14.0	CHEMBL5855	Homo sapiens	IC50	nM	14.0
287498	17669843	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672278	=	IC50	nM	20.0	CHEMBL5855	Homo sapiens	IC50	nM	20.0
287499	17669844	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H](C)c1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672279	=	IC50	nM	30.0	CHEMBL5855	Homo sapiens	IC50	nM	30.0
287500	17669845	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(CN)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672280	=	IC50	nM	8.6	CHEMBL5855	Homo sapiens	IC50	nM	8.6
287501	17669846	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(S(=O)(=O)NCCCl)cc1		CHEMBL3639711	=	IC50	nM	70.0	CHEMBL5855	Homo sapiens	IC50	nM	70.0
287502	17669847	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672281	=	IC50	nM	45.0	CHEMBL5855	Homo sapiens	IC50	nM	45.0
287503	17669848	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	O=c1[nH]c2ccc(O)c(-c3ccc(S(=O)(=O)NCCCl)cc3)c2c2c1CCC2		CHEMBL3672282	=	IC50	nM	13.0	CHEMBL5855	Homo sapiens	IC50	nM	13.0
287504	17669849	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@H](NC)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672283	=	IC50	nM	1.3	CHEMBL5855	Homo sapiens	IC50	nM	1.3
287505	17669850	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@@H](N)c1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672284	=	IC50	nM	47.0	CHEMBL5855	Homo sapiens	IC50	nM	47.0
287506	17669851	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@H](c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)N(C)C		CHEMBL3672285	=	IC50	nM	2.5	CHEMBL5855	Homo sapiens	IC50	nM	2.5
287507	17669852	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@H](NC)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672286	=	IC50	nM	9.4	CHEMBL5855	Homo sapiens	IC50	nM	9.4
287508	17669853	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@@H](N)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672287	=	IC50	nM	18.0	CHEMBL5855	Homo sapiens	IC50	nM	18.0
287509	17669854	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@@H](N)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672288	=	IC50	nM	26.0	CHEMBL5855	Homo sapiens	IC50	nM	26.0
287510	17669855	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672289	=	IC50	nM	0.64	CHEMBL5855	Homo sapiens	IC50	nM	0.64
287511	17669856	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc([C@@H](C)CN)cc1		CHEMBL3672290	=	IC50	nM	2.0	CHEMBL5855	Homo sapiens	IC50	nM	2.0
287512	17669857	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(C#N)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672291	=	IC50	nM	13.0	CHEMBL5855	Homo sapiens	IC50	nM	13.0
287513	17669858	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@H](CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672292	=	IC50	nM	1.3	CHEMBL5855	Homo sapiens	IC50	nM	1.3
287514	17669859	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCCc1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672293	=	IC50	nM	58.0	CHEMBL5855	Homo sapiens	IC50	nM	58.0
287515	17669860	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](CN)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672294	=	IC50	nM	4.4	CHEMBL5855	Homo sapiens	IC50	nM	4.4
287516	17669861	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)CN)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672295	=	IC50	nM	2.6	CHEMBL5855	Homo sapiens	IC50	nM	2.6
287517	17669862	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)CN)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672295	=	IC50	nM	8.9	CHEMBL5855	Homo sapiens	IC50	nM	8.9
287518	17669863	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@H](CN(C)C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672296	=	IC50	nM	4.0	CHEMBL5855	Homo sapiens	IC50	nM	4.0
287519	17669864	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672297	=	IC50	nM	1.5	CHEMBL5855	Homo sapiens	IC50	nM	1.5
287520	17669865	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](CN)c1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672298	=	IC50	nM	17.0	CHEMBL5855	Homo sapiens	IC50	nM	17.0
287521	17669866	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(C(C)CN)c(F)c1		CHEMBL3672299	=	IC50	nM	3.0	CHEMBL5855	Homo sapiens	IC50	nM	3.0
287522	17669867	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@H](CN)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672300	=	IC50	nM	33.0	CHEMBL5855	Homo sapiens	IC50	nM	33.0
287523	17669868	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@H](C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672301	=	IC50	nM	1.3	CHEMBL5855	Homo sapiens	IC50	nM	1.3
287524	17669869	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](CN(C)C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672302	=	IC50	nM	2.5	CHEMBL5855	Homo sapiens	IC50	nM	2.5
287525	17669870	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@H](C)c1ccc(-c2c(OC)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672303	=	IC50	nM	3.0	CHEMBL5855	Homo sapiens	IC50	nM	3.0
287526	17669871	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(C)CN)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672304	=	IC50	nM	5.1	CHEMBL5855	Homo sapiens	IC50	nM	5.1
287527	17669872	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(CCN)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672305	=	IC50	nM	19.0	CHEMBL5855	Homo sapiens	IC50	nM	19.0
287528	17669873	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(C)CN(C)C)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672306	=	IC50	nM	46.0	CHEMBL5855	Homo sapiens	IC50	nM	46.0
287529	17669874	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@@H](C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672307	=	IC50	nM	2.8	CHEMBL5855	Homo sapiens	IC50	nM	2.8
287530	17669875	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(Cl)c2[nH]c(=O)c3sccc3c2c1-c1ccc([C@@H](C)CN)cc1		CHEMBL3672308	=	IC50	nM	20.0	CHEMBL5855	Homo sapiens	IC50	nM	20.0
287531	17669876	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(CCl)NS(=O)(=O)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672309	=	IC50	nM	15.0	CHEMBL5855	Homo sapiens	IC50	nM	15.0
287532	17669877	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(CC)(CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672310	=	IC50	nM	1.8	CHEMBL5855	Homo sapiens	IC50	nM	1.8
287533	17669878	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1cc(Cl)c(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1O		CHEMBL3672311	=	IC50	nM	16.0	CHEMBL5855	Homo sapiens	IC50	nM	16.0
287534	17669879	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672312	=	IC50	nM	19.0	CHEMBL5855	Homo sapiens	IC50	nM	19.0
287535	17669880	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@@H](C)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672313	=	IC50	nM	60.0	CHEMBL5855	Homo sapiens	IC50	nM	60.0
287536	17669881	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc(CCN)c(F)c1		CHEMBL3672314	=	IC50	nM	57.0	CHEMBL5855	Homo sapiens	IC50	nM	57.0
287537	17669882	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(CCN)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672315	=	IC50	nM	4.7	CHEMBL5855	Homo sapiens	IC50	nM	4.7
287538	17669883	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(Cl)c2[nH]c(=O)c3sccc3c2c1-c1ccc(CCN)c(F)c1		CHEMBL3672316	=	IC50	nM	87.0	CHEMBL5855	Homo sapiens	IC50	nM	87.0
287539	17669884	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672317	=	IC50	nM	5.5	CHEMBL5855	Homo sapiens	IC50	nM	5.5
287540	17669885	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1cc(Br)c(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1O		CHEMBL3672318	=	IC50	nM	6.4	CHEMBL5855	Homo sapiens	IC50	nM	6.4
287541	17669886	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@H](C)N)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672319	=	IC50	nM	16.0	CHEMBL5855	Homo sapiens	IC50	nM	16.0
287542	17669887	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(CCC#N)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672320	=	IC50	nM	92.0	CHEMBL5855	Homo sapiens	IC50	nM	92.0
287543	17669888	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(C)(C)CN)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672321	=	IC50	nM	39.0	CHEMBL5855	Homo sapiens	IC50	nM	39.0
287544	17669889	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@H](C)CN)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672322	=	IC50	nM	16.0	CHEMBL5855	Homo sapiens	IC50	nM	16.0
287545	17669890	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCC(c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1)C1CCCC1		CHEMBL3672323	=	IC50	nM	4.6	CHEMBL5855	Homo sapiens	IC50	nM	4.6
287546	17669891	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(C(CN)C2CCCC2)cc1		CHEMBL3672324	=	IC50	nM	23.0	CHEMBL5855	Homo sapiens	IC50	nM	23.0
287547	17669892	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(CC(C)N)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672325	=	IC50	nM	37.0	CHEMBL5855	Homo sapiens	IC50	nM	37.0
287548	17669893	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCCc1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672326	=	IC50	nM	45.0	CHEMBL5855	Homo sapiens	IC50	nM	45.0
287549	17669894	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(CN)c1ccc(-c2c(O)cc(Br)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672327	=	IC50	nM	72.0	CHEMBL5855	Homo sapiens	IC50	nM	72.0
287550	17669895	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc(C2(CN)CC2)cc1		CHEMBL3672328	=	IC50	nM	55.0	CHEMBL5855	Homo sapiens	IC50	nM	55.0
287551	17669896	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)C(CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672329	=	IC50	nM	1.4	CHEMBL5855	Homo sapiens	IC50	nM	1.4
287552	17669897	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1ccc2[nH]c(=O)c3sccc3c2c1-c1ccc(C(CN)C(C)C)cc1		CHEMBL3672330	=	IC50	nM	4.1	CHEMBL5855	Homo sapiens	IC50	nM	4.1
287553	17669898	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C3(CN)CC3)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672331	=	IC50	nM	9.6	CHEMBL5855	Homo sapiens	IC50	nM	9.6
287554	17669899	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCCc1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672332	=	IC50	nM	25.0	CHEMBL5855	Homo sapiens	IC50	nM	25.0
287555	17669900	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(CN)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672333	=	IC50	nM	75.0	CHEMBL5855	Homo sapiens	IC50	nM	75.0
287556	17669901	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H](C)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672334	=	IC50	nM	12.0	CHEMBL5855	Homo sapiens	IC50	nM	12.0
287557	17669902	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc(CCN)c(Cl)c1		CHEMBL3672335	=	IC50	nM	33.0	CHEMBL5855	Homo sapiens	IC50	nM	33.0
287558	17669903	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(CCN)c(Cl)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672336	=	IC50	nM	3.0	CHEMBL5855	Homo sapiens	IC50	nM	3.0
287559	17669904	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CN[C@H](C)c1ccc(-c2c(OC)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672337	=	IC50	nM	67.0	CHEMBL5855	Homo sapiens	IC50	nM	67.0
287560	17669905	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCCc1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1Cl		CHEMBL3672338	=	IC50	nM	3.9	CHEMBL5855	Homo sapiens	IC50	nM	3.9
287561	17669906	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(C)(CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672339	=	IC50	nM	1.0	CHEMBL5855	Homo sapiens	IC50	nM	1.0
287562	17669907	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc(C(C)CN)c(F)c1		CHEMBL3672340	=	IC50	nM	40.0	CHEMBL5855	Homo sapiens	IC50	nM	40.0
287563	17669908	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(CN)C(C)C)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672341	=	IC50	nM	18.0	CHEMBL5855	Homo sapiens	IC50	nM	18.0
287564	17669909	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(CN)c1ccc(-c2c(OC)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672342	=	IC50	nM	63.0	CHEMBL5855	Homo sapiens	IC50	nM	63.0
287565	17669910	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(C)(C)CN)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672343	=	IC50	nM	22.0	CHEMBL5855	Homo sapiens	IC50	nM	22.0
287566	17669911	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC(CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1Cl		CHEMBL3672344	=	IC50	nM	10.0	CHEMBL5855	Homo sapiens	IC50	nM	10.0
287567	17669912	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc(C(CN)C(C)C)c(F)c1		CHEMBL3672345	=	IC50	nM	47.0	CHEMBL5855	Homo sapiens	IC50	nM	47.0
287568	17669913	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCC(c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1)C(C)C		CHEMBL3672346	=	IC50	nM	50.0	CHEMBL5855	Homo sapiens	IC50	nM	50.0
287569	17669914	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCC(C)c1ccc(-c2c(OC)cc(C)c3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672347	=	IC50	nM	43.0	CHEMBL5855	Homo sapiens	IC50	nM	43.0
287570	17669915	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(CN)C(C)C)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672348	=	IC50	nM	20.0	CHEMBL5855	Homo sapiens	IC50	nM	20.0
287571	17669916	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C3(CN)CCC3)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672349	=	IC50	nM	10.0	CHEMBL5855	Homo sapiens	IC50	nM	10.0
287572	17669917	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(CN)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672350	=	IC50	nM	15.0	CHEMBL5855	Homo sapiens	IC50	nM	15.0
287573	17669918	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCC(C)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672351	=	IC50	nM	8.9	CHEMBL5855	Homo sapiens	IC50	nM	8.9
287574	17669919	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCC(c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1F)C(C)C		CHEMBL3672352	=	IC50	nM	17.0	CHEMBL5855	Homo sapiens	IC50	nM	17.0
287575	17669920	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc(C2(CN)CCC2)cc1		CHEMBL3672353	=	IC50	nM	35.0	CHEMBL5855	Homo sapiens	IC50	nM	35.0
287576	17669921	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@H](C)c1ccc(-c2c(OC)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672354	=	IC50	nM	32.0	CHEMBL5855	Homo sapiens	IC50	nM	32.0
287577	17669922	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCC1(c2ccc(-c3c(O)ccc4[nH]c(=O)c5sccc5c34)cc2)CCC1		CHEMBL3672355	=	IC50	nM	1.7	CHEMBL5855	Homo sapiens	IC50	nM	1.7
287578	17669923	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C3CCCNC3)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672356	=	IC50	nM	75.0	CHEMBL5855	Homo sapiens	IC50	nM	75.0
287579	17669924	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@H](C)CN)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672357	=	IC50	nM	14.0	CHEMBL5855	Homo sapiens	IC50	nM	14.0
287580	17669925	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@H](C)CN)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672357	=	IC50	nM	13.0	CHEMBL5855	Homo sapiens	IC50	nM	13.0
287581	17669926	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc([C@@H](C)CN)cc1		CHEMBL3672358	=	IC50	nM	15.0	CHEMBL5855	Homo sapiens	IC50	nM	15.0
287582	17669927	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@H](C)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672359	=	IC50	nM	7.3	CHEMBL5855	Homo sapiens	IC50	nM	7.3
287583	17669928	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@H](C)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672359	=	IC50	nM	18.0	CHEMBL5855	Homo sapiens	IC50	nM	18.0
287584	17669929	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(CN)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672360	=	IC50	nM	0.74	CHEMBL5855	Homo sapiens	IC50	nM	0.74
287585	17669930	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc([C@H](C)CN)c(F)c1		CHEMBL3672361	=	IC50	nM	54.0	CHEMBL5855	Homo sapiens	IC50	nM	54.0
287586	17669931	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)CN(C)C)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672362	=	IC50	nM	17.0	CHEMBL5855	Homo sapiens	IC50	nM	17.0
287587	17669932	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCC(CN)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672363	=	IC50	nM	19.0	CHEMBL5855	Homo sapiens	IC50	nM	19.0
287588	17669933	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@H](C)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672364	=	IC50	nM	8.1	CHEMBL5855	Homo sapiens	IC50	nM	8.1
287589	17669934	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNC[C@H](C)c1ccc(-c2c(OC)cc(C)c3[nH]c(=O)c4sccc4c23)cc1F		CHEMBL3672365	=	IC50	nM	33.0	CHEMBL5855	Homo sapiens	IC50	nM	33.0
287590	17669935	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sccc3c2c1-c1ccc([C@@H](C)CN)c(F)c1		CHEMBL3672366	=	IC50	nM	22.0	CHEMBL5855	Homo sapiens	IC50	nM	22.0
287591	17669936	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)CN)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672367	=	IC50	nM	3.6	CHEMBL5855	Homo sapiens	IC50	nM	3.6
287592	17669937	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)CN)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672367	=	IC50	nM	3.4	CHEMBL5855	Homo sapiens	IC50	nM	3.4
287593	17669938	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(Cl)c2[nH]c(=O)c3sccc3c2c1-c1ccc(C2(CN)CCC2)cc1		CHEMBL3672368	=	IC50	nM	96.0	CHEMBL5855	Homo sapiens	IC50	nM	96.0
287594	17669939	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)CN(C)C)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672369	=	IC50	nM	32.0	CHEMBL5855	Homo sapiens	IC50	nM	32.0
287595	17669940	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(C)(C)N)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672370	=	IC50	nM	8.3	CHEMBL5855	Homo sapiens	IC50	nM	8.3
287596	17669941	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc2c(s1)c(=O)[nH]c1c(C)cc(O)c(-c3ccc([C@@H](C)CN)cc3)c12		CHEMBL3672371	=	IC50	nM	12.0	CHEMBL5855	Homo sapiens	IC50	nM	12.0
287597	17669942	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sc(C)cc3c2c1-c1ccc([C@@H](C)CN)cc1		CHEMBL3672372	=	IC50	nM	38.0	CHEMBL5855	Homo sapiens	IC50	nM	38.0
287598	17669943	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	C[C@@H](CN(C)C)c1ccc(-c2c(O)cc(Cl)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672373	=	IC50	nM	43.0	CHEMBL5855	Homo sapiens	IC50	nM	43.0
287599	17669944	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@@H](CN)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672374	=	IC50	nM	40.0	CHEMBL5855	Homo sapiens	IC50	nM	40.0
287600	17669945	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)CN)cc2)c2c1[nH]c(=O)c1sc(Cl)cc12		CHEMBL3672375	=	IC50	nM	4.0	CHEMBL5855	Homo sapiens	IC50	nM	4.0
287601	17669946	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sc(Cl)cc3c2c1-c1ccc([C@@H](C)CN)cc1		CHEMBL3672376	=	IC50	nM	11.0	CHEMBL5855	Homo sapiens	IC50	nM	11.0
287602	17669947	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CNCCc1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672377	=	IC50	nM	55.0	CHEMBL5855	Homo sapiens	IC50	nM	55.0
287603	17669948	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C3(CN(C)C)CCC3)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672378	=	IC50	nM	42.0	CHEMBL5855	Homo sapiens	IC50	nM	42.0
287604	17669949	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(C)c2[nH]c(=O)c3sc(F)cc3c2c1-c1ccc([C@@H](C)CN)cc1		CHEMBL3672379	=	IC50	nM	22.0	CHEMBL5855	Homo sapiens	IC50	nM	22.0
287605	17669950	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CCN(C)C[C@H](C)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3639712	=	IC50	nM	76.0	CHEMBL5855	Homo sapiens	IC50	nM	76.0
287606	17669951	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	CC[C@@H](CNC)c1ccc(-c2c(O)cc(C)c3[nH]c(=O)c4sccc4c23)cc1		CHEMBL3672380	=	IC50	nM	85.0	CHEMBL5855	Homo sapiens	IC50	nM	85.0
287607	17669952	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@@H](C)CN)cc2)c2c1[nH]c(=O)c1sc(F)cc12		CHEMBL3672381	=	IC50	nM	3.7	CHEMBL5855	Homo sapiens	IC50	nM	3.7
287608	17669953	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	COc1cc(Br)c2[nH]c(=O)c3sccc3c2c1-c1ccc(C2(CN)CC2)cc1		CHEMBL3672382	=	IC50	nM	70.0	CHEMBL5855	Homo sapiens	IC50	nM	70.0
287609	17669954	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc([C@H](C)CN(C)C)c(F)c2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672383	=	IC50	nM	58.0	CHEMBL5855	Homo sapiens	IC50	nM	58.0
287610	17669955	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(N(C)CCN)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672384	=	IC50	nM	60.0	CHEMBL5855	Homo sapiens	IC50	nM	60.0
287611	17669956	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	NCC1(c2ccc(-c3c(O)cc(Br)c4[nH]c(=O)c5sccc5c34)cc2)CC1		CHEMBL3672385	=	IC50	nM	51.0	CHEMBL5855	Homo sapiens	IC50	nM	51.0
287612	17669957	CHEMBL3705860	Kinase Assay: PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature.	B	Cc1cc(O)c(-c2ccc(C(C)CS(N)(=O)=O)cc2)c2c1[nH]c(=O)c1sccc12		CHEMBL3672386	=	IC50	nM	82.0	CHEMBL5855	Homo sapiens	IC50	nM	82.0
Inactive	17920843	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920844	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920845	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920846	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920847	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920848	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920849	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920850	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920851	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920852	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920853	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920854	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920855	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920856	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920857	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920858	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920859	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920860	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920861	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920862	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920863	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920864	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920865	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920866	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920867	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920868	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920869	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920870	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920871	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920872	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920873	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920874	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920875	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920876	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920877	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920878	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920879	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920880	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920881	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920882	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920883	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920884	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920885	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920886	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920887	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920888	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920889	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920890	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920891	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Active	17920892	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	=	Kd	nM	2381.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	2381.0
Inactive	17920893	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920894	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920895	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920896	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920897	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920898	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920899	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920900	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920901	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920902	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920903	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920904	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920905	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920906	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920907	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920908	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920909	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920910	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920911	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920912	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920913	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920914	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920915	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920916	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920917	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920918	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920919	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920920	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920921	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920922	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920923	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920924	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920925	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920926	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920927	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920928	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920929	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920930	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920931	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920932	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920933	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920934	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920935	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920936	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920937	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920938	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920939	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920940	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920941	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920942	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920943	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920944	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920945	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920946	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920947	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920948	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920949	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920950	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920951	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920952	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Active	17920953	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	1099.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	1099.0
Inactive	17920954	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920955	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920956	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920957	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920958	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920959	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920960	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920961	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920962	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920963	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920964	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920965	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920966	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920967	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920968	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920969	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920970	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920971	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920972	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920973	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920974	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920975	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920976	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920977	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920978	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920979	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920980	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920981	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920982	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920983	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920984	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920985	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920986	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920987	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920988	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920989	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920990	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920991	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920992	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920993	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920994	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920995	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920996	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920997	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920998	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17920999	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921000	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921001	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921002	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921003	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921004	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921005	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921006	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921007	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921008	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921009	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921010	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921011	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921012	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921013	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921014	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921015	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921016	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921017	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921018	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921019	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921020	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921021	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921022	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921023	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921024	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921025	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921026	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921027	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921028	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921029	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921030	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921031	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921032	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921033	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921034	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Active	17921035	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	587.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	587.0
Inactive	17921036	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921037	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921038	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921039	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921040	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921041	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921042	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921043	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921044	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921045	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921046	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921047	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Active	17921048	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	=	Kd	nM	365.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	365.0
Inactive	17921049	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921050	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921051	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Active	17921052	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	=	Kd	nM	477.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	477.0
Inactive	17921053	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921054	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921055	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921056	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921057	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921058	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921059	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921060	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921061	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921062	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921063	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921064	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921065	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921066	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921067	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921068	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921069	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921070	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921071	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921072	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921073	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921074	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921075	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921076	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921077	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921078	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921079	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921080	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921081	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921082	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921083	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921084	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17921085	CHEMBL3991798	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL5855	Homo sapiens	Kd apparent	nM	30000.0
	17964928	CHEMBL3995037	Inhibition of human NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1		CHEMBL4060295	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	18114226	CHEMBL4025268	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	18153263	CHEMBL4034422	Inhibition of NEK1 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	5.6	CHEMBL5855	Homo sapiens	INH	%	5.6
	18203792	CHEMBL4044079	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	73.0	CHEMBL5855	Homo sapiens	Activity	%	73.0
	18211539	CHEMBL4045774	Inhibition of NEK1 conserved Lys2 (DIKSQNIFLTK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	10.0	CHEMBL5855	Homo sapiens	INH	%	10.0
	18211919	CHEMBL4046015	Inhibition of NEK1 conserved Lys2 (DIKSQNIFLTK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	5.5	CHEMBL5855	Homo sapiens	INH	%	5.5
	18218051	CHEMBL4047105	Inhibition of NEK1 (unknown origin) at 10 uM using [33P]-ATP after 20 to 40 mins by scintillation counting method	B	Cc1ccc(NC(=O)c2c(N=Cc3ccc4ccccc4c3)c(C#N)c3n2CCC3)cc1		CHEMBL4079032	=	Inhibition	%	-8.0	CHEMBL5855	Homo sapiens	INH	%	-8.0
	18218052	CHEMBL4047105	Inhibition of NEK1 (unknown origin) at 10 uM using [33P]-ATP after 20 to 40 mins by scintillation counting method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Inhibition	%	-2.0	CHEMBL5855	Homo sapiens	INH	%	-2.0
	18253881	CHEMBL4055225	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	18253882	CHEMBL4055225	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	92.0	CHEMBL5855	Homo sapiens	Activity	%	92.0
	18265809	CHEMBL4057259	Inhibition of NEK1 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	3.7	CHEMBL5855	Homo sapiens	INH	%	3.7
	18266007	CHEMBL4057457	Inhibition of NEK1 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	0.3	CHEMBL5855	Homo sapiens	INH	%	0.3
	18275133	CHEMBL4118423	Inhibition of NEK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKSQNIFLTK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl	Outside typical range	CHEMBL3883384	=	Inhibition	%	-12.1	CHEMBL5855	Homo sapiens	INH	%	-12.1
	18275134	CHEMBL4118423	Inhibition of NEK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKSQNIFLTK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl		CHEMBL3884839	=	Inhibition	%	-7.4	CHEMBL5855	Homo sapiens	INH	%	-7.4
	18275135	CHEMBL4118423	Inhibition of NEK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKSQNIFLTK probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O	Outside typical range	CHEMBL1077979	=	Inhibition	%	-11.2	CHEMBL5855	Homo sapiens	INH	%	-11.2
	18282138	CHEMBL4120093	Inhibition of recombinant full length GST-tagged human NEK1 expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	5.7	CHEMBL5855	Homo sapiens	INH	%	5.7
	18282457	CHEMBL4120093	Inhibition of recombinant full length GST-tagged human NEK1 expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	3.6	CHEMBL5855	Homo sapiens	INH	%	3.6
	18282788	CHEMBL4120373	Inhibition of NEK1 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	3.7	CHEMBL5855	Homo sapiens	INH	%	3.7
	18283015	CHEMBL4120600	Inhibition of NEK1 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	1.3	CHEMBL5855	Homo sapiens	INH	%	1.3
	18283239	CHEMBL4120824	Inhibition of NEK1 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	-1.3	CHEMBL5855	Homo sapiens	INH	%	-1.3
	18403013	CHEMBL4150531	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system by Kinomescan method	B	CN(C)[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H](c5ccc6ccncc6c5)[C@@]4(C)CC[C@@H]32)C1		CHEMBL4167193	>	IC50	nM	10000.0	CHEMBL5855	Homo sapiens	IC50	nM	10000.0
	18403016	CHEMBL4150528	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	CN(C)[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H](c5ccc6ccncc6c5)[C@@]4(C)CC[C@@H]32)C1		CHEMBL4167193	>	Inhibition	%	90.0	CHEMBL5855	Homo sapiens	INH	%	90.0
	18440334	CHEMBL4157158	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	92.0	CHEMBL5855	Homo sapiens	Activity	%	92.0
	18484290	CHEMBL4185937	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	94.0	CHEMBL5855	Homo sapiens	Activity	%	94.0
	18484774	CHEMBL4185937	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	18507682	CHEMBL4191080	Inhibition of recombinant human NEK1 (1 to 505 residues) at 1 uM using RLGRDKYKTLRQIRQ as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-4.0	CHEMBL5855	Homo sapiens	INH	%	-4.0
	18653491	CHEMBL4230158	Inhibition of NEK1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	-1.0	CHEMBL5855	Homo sapiens	INH	%	-1.0
	18653492	CHEMBL4230158	Inhibition of NEK1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	-5.0	CHEMBL5855	Homo sapiens	INH	%	-5.0
	18655398	CHEMBL4230837	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	18665444	CHEMBL4233364	Inhibition of NEK1 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	1000.0	CHEMBL5855	Homo sapiens	IC50	nM	1000.0
	18674781	CHEMBL4235395	Inhibition of NEK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	2000.0	CHEMBL5855	Homo sapiens	Ki	nM	2000.0
	18674782	CHEMBL4235395	Inhibition of NEK1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	2000.0	CHEMBL5855	Homo sapiens	Ki	nM	2000.0
Not Determined	18674783	CHEMBL4235395	Inhibition of NEK1 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525		Ki			CHEMBL5855	Homo sapiens	Ki		
	18697663	CHEMBL4254336	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1		CHEMBL4281348	=	Activity	%	60.0	CHEMBL5855	Homo sapiens	Activity	%	60.0
	18751168	CHEMBL4263877	Inhibition of NEK1 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	21.0	CHEMBL5855	Homo sapiens	INH	%	21.0
	18752089	CHEMBL4264426	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	85.0	CHEMBL5855	Homo sapiens	Activity	%	85.0
	18848118	CHEMBL4305114	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as enzyme remaining activity at 1 uM by Kinomescan assay relative to control	B	O=C(CC(=O)Nc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1)Nc1cccc(F)c1		CHEMBL4446361	=	Activity	%	0.0	CHEMBL5855	Homo sapiens	Activity	%	0.0
	18848126	CHEMBL4305122	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system after 1 hr by Z-LYTE assay	B	O=C(CC(=O)Nc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1)Nc1cccc(F)c1		CHEMBL4446361	>	IC50	nM	10000.0	CHEMBL5855	Homo sapiens	IC50	nM	10000.0
	18858090	CHEMBL4307936	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	18892668	CHEMBL4314581	Inhibition of recombinant human NEK1 (1 to 505 residues) assessed as residual activity at 10 uM using RLGRDKYKTLRQIRQ as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	114.0	CHEMBL5855	Homo sapiens	Activity	%	114.0
	18895035	CHEMBL4315517	Inhibition of recombinant human N-terminal GST-tagged full length NEK1 expressed in baculovirus infected Sf9 insect cells assessed as enzyme activity incubated for 15 mins by [gamma-33]ATP based scintillation counting method relative to control	B	CC(C)C/C=N/c1c(C#N)c2n(c1C(=O)Nc1ccc(Br)cc1)CCC2		CHEMBL4592358	=	Activity	%	-14.0	CHEMBL5855	Homo sapiens	Activity	%	-14.0
	18895054	CHEMBL4315517	Inhibition of recombinant human N-terminal GST-tagged full length NEK1 expressed in baculovirus infected Sf9 insect cells assessed as enzyme activity incubated for 15 mins by [gamma-33]ATP based scintillation counting method relative to control	B	CC/C=N/c1c(C#N)c2n(c1C(=O)Nc1ccccc1)CCC2		CHEMBL4527978	=	Activity	%	-1.0	CHEMBL5855	Homo sapiens	Activity	%	-1.0
	18895073	CHEMBL4315517	Inhibition of recombinant human N-terminal GST-tagged full length NEK1 expressed in baculovirus infected Sf9 insect cells assessed as enzyme activity incubated for 15 mins by [gamma-33]ATP based scintillation counting method relative to control	B	CCC1SCC(=O)N1c1c(C#N)c2n(c1C(=O)Nc1ccccc1)CCC2		CHEMBL4471323	=	Activity	%	10.0	CHEMBL5855	Homo sapiens	Activity	%	10.0
	18895092	CHEMBL4315517	Inhibition of recombinant human N-terminal GST-tagged full length NEK1 expressed in baculovirus infected Sf9 insect cells assessed as enzyme activity incubated for 15 mins by [gamma-33]ATP based scintillation counting method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Activity	%	-2.0	CHEMBL5855	Homo sapiens	Activity	%	-2.0
	18938135	CHEMBL4327794	Inhibition of human NEK1 assessed as residual activity at 1 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	102.58	CHEMBL5855	Homo sapiens	Activity	%	102.58
	18938136	CHEMBL4327794	Inhibition of human NEK1 assessed as residual activity at 1 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	99.07	CHEMBL5855	Homo sapiens	Activity	%	99.07
	18938639	CHEMBL4328158	Inhibition of human NEK1 assessed as residual activity at 100 uM using MBP as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL5855	Homo sapiens	Activity	%	65.0
	18939019	CHEMBL4328522	Inhibition of human NEK1 using MBP as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	18.4	CHEMBL5855	Homo sapiens	IC50	10'-8M	1.84
	18958668	CHEMBL4333523	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	79.0	CHEMBL5855	Homo sapiens	Activity	%	79.0
	18964515	CHEMBL4335198	Inhibition of recombinant human NEK1 (1 to 505 residues) assessed as residual activity at 1 uM using RLGRDKYKTLRQI as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	107.0	CHEMBL5855	Homo sapiens	Activity	%	107.0
	18964516	CHEMBL4335198	Inhibition of recombinant human NEK1 (1 to 505 residues) assessed as residual activity at 1 uM using RLGRDKYKTLRQI as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	95.0	CHEMBL5855	Homo sapiens	Activity	%	95.0
	18972012	CHEMBL4337022	Inhibition of recombinant human NEK1 (1 to 505 residues) assessed as residual activity at 10 uM using RLGRDKYKTLRQI as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	23.0	CHEMBL5855	Homo sapiens	Activity	%	23.0
	19030023	CHEMBL4349162	Inhibition of recombinant human GST-tagged NEK1 catalytic domain (1 to 505 amino acids) expressed in baculovirus expression system assessed as enzyme residual activity at 0.4 uM using fluorophore-labeled serine/threonine-07 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1		CHEMBL4443805	=	Activity	%	89.0	CHEMBL5855	Homo sapiens	Activity	%	89.0
Not Active	19040070	CHEMBL4351974	Inhibition of recombinant human NEK1 (1 to 505 residues) at 10 uM using RLGRDKYKTLRQIRQ as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL5855	Homo sapiens	INH		
Active	19041203	CHEMBL4352464	Inhibition of human NEK1 at 10 uM using MBP as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL5855	Homo sapiens	INH		
	19059714	CHEMBL4358015	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	19090279	CHEMBL4365853	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	19092032	CHEMBL4366506	Inhibition of human NEK1 at 100 nM using MBP as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	19.03	CHEMBL5855	Homo sapiens	INH	%	19.03
	19114474	CHEMBL4371445	Binding affinity to NEK1 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4cc(F)ccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4443828	=	Kd	nM	5146.0	CHEMBL5855	Homo sapiens	Kd(free)	uM	5.146
	19114715	CHEMBL4371445	Binding affinity to NEK1 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4c(F)cccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4462318	=	Kd	nM	5043.0	CHEMBL5855	Homo sapiens	Kd(free)	uM	5.043
	19144673	CHEMBL4377689	Inhibition of recombinant human NEK1 (1 to 505 residues) at 1 uM using RLGRDKYKTLRQIRQ as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	69.0	CHEMBL5855	Homo sapiens	INH	%	69.0
	19146884	CHEMBL4378908	Inhibition of recombinant human NEK1 (1 to 505 residues) at 10 uM using RLGRDKYKTLRQIRQ as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	-6.0	CHEMBL5855	Homo sapiens	INH	%	-6.0
	19147958	CHEMBL4379244	Inhibition of recombinant human NEK1 (1 to 505 residues) using RLGRDKYKTLRQI as substrate measured after 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL5855	Homo sapiens	IC50	uM	10.0
	19159542	CHEMBL4382646	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	68.0	CHEMBL5855	Homo sapiens	Activity	%	68.0
	19181098	CHEMBL4387309	Inhibition of recombinant full length human GST-tagged NEK1 catalytic domain (1 to 505 amino acids) expressed in baculovirus expression system at 0.1 uM using serine/threonine-7 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	14.0	CHEMBL5855	Homo sapiens	INH	%	14.0
	19181323	CHEMBL4387309	Inhibition of recombinant full length human GST-tagged NEK1 catalytic domain (1 to 505 amino acids) expressed in baculovirus expression system at 0.1 uM using serine/threonine-7 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	19191465	CHEMBL4389365	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	100.0	CHEMBL5855	Homo sapiens	INH	%	100.0
	19192028	CHEMBL4389842	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	100.0	CHEMBL5855	Homo sapiens	INH	%	100.0
	19200284	CHEMBL4391468	Binding affinity to wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	80.0	CHEMBL5855	Homo sapiens	Activity	%	80.0
Active	19218915	CHEMBL4394530	Binding affinity to NEK1 in human SUM159 cell lysates by multiplexed inhibitor bead profiling-based LC-MS/MS analysis	B	C#Cc1cccc(Nc2ccnc3cc(OC)c(OC)cc23)c1		CHEMBL1092250		Activity			CHEMBL5855	Homo sapiens	Activity		
	19266529	CHEMBL4405479	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL5855	Homo sapiens	INH	%	50.0
	19276060	CHEMBL4408063	Inhibition of recombinant human NEK1 (1 to 505 residues) at 1 uM using RLGRDKYKTLRQIRQ as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	72.0	CHEMBL5855	Homo sapiens	INH	%	72.0
	20600601	CHEMBL4603553	Inhibition of recombinant human GST-tagged NEK1 catalytic domain (1 to 505 residues) expressed in baculovirus expression system using serine/threonine-7 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL5855	Homo sapiens	IC50	uM	100.0
	20601680	CHEMBL4603812	Inhibition of recombinant human GST-tagged NEK1 (1 to 505 residues) expressed in baculovirus expression system using Ser/Thr07 peptide as substrate at 0.6 uM incubated for 1 hr by Z'lyte assay relative to control	B	C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4646281	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	22392118	CHEMBL4667213	Inhibition of recombinant human GST-tagged NEK1 (1 to 505 residues) expressed in baculovirus expression system using Ser/Thr 07 as substrate at 10 uM incubated for 60 mins by Z'-lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	9.0	CHEMBL5855	Homo sapiens	INH	%	9.0
	22423409	CHEMBL4674280	Inhibition of human NEK1 using MBP as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	79.55	CHEMBL5855	Homo sapiens	Activity	%	79.55
	22423410	CHEMBL4674280	Inhibition of human NEK1 using MBP as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	85.72	CHEMBL5855	Homo sapiens	Activity	%	85.72
	22752578	CHEMBL4700118	Inhibition of human NEK1 by kinase-profiling analysis	B	C#Cc1nc(Nc2ccccc2)nc2[nH]cnc12		CHEMBL4094562	=	IC50	nM	20800.0	CHEMBL5855	Homo sapiens	IC50	uM	20.8
	22752579	CHEMBL4700119	Inhibition of human NEK1 at 10 uM by kinase-profiling analysis	B	C#Cc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc2[nH]cnc12		CHEMBL4074015	=	Inhibition	%	58.0	CHEMBL5855	Homo sapiens	INH	%	58.0
	22836336	CHEMBL4718878	Inhibition of recombinant human GST-tagged NEK1 (1 to 505 residues) expressed in baculovirus expression system at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-8.0	CHEMBL5855	Homo sapiens	INH	%	-8.0
	22836337	CHEMBL4718878	Inhibition of recombinant human GST-tagged NEK1 (1 to 505 residues) expressed in baculovirus expression system at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	OCC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1		CHEMBL4786776	=	Inhibition	%	13.0	CHEMBL5855	Homo sapiens	INH	%	13.0
	22836338	CHEMBL4718878	Inhibition of recombinant human GST-tagged NEK1 (1 to 505 residues) expressed in baculovirus expression system at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	CN(C)CCNCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1F		CHEMBL4748367	=	Inhibition	%	15.0	CHEMBL5855	Homo sapiens	INH	%	15.0
	22836339	CHEMBL4718878	Inhibition of recombinant human GST-tagged NEK1 (1 to 505 residues) expressed in baculovirus expression system at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	CCOc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1		CHEMBL4776396	=	Inhibition	%	8.0	CHEMBL5855	Homo sapiens	INH	%	8.0
	22836340	CHEMBL4718878	Inhibition of recombinant human GST-tagged NEK1 (1 to 505 residues) expressed in baculovirus expression system at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	COc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1		CHEMBL4783569	=	Inhibition	%	1.0	CHEMBL5855	Homo sapiens	INH	%	1.0
	22836341	CHEMBL4718878	Inhibition of recombinant human GST-tagged NEK1 (1 to 505 residues) expressed in baculovirus expression system at 500 nM using Ser/Thr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1		CHEMBL4780286	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	22843645	CHEMBL4720631	Inhibition of human NEK1 using MBP as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	9.22	CHEMBL5855	Homo sapiens	IC50	10^-9M	9.22
	22843994	CHEMBL4720980	Inhibition of human NEK1 assessed as residual activity using MBP as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	94.78	CHEMBL5855	Homo sapiens	Activity	%	94.78
	22844773	CHEMBL4721448	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	90.78	CHEMBL5855	Homo sapiens	Activity	%	90.78
	22946166	CHEMBL4742631	Inhibition of NEK1 (unknown origin) at 10 uM relative to control	B	CN(C)[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H](c5ccc6ccncc6c5)[C@@]4(C)CC[C@@H]32)C1		CHEMBL4167193	>	Inhibition	%	90.0	CHEMBL5855	Homo sapiens	INH	%	90.0
	22946168	CHEMBL4742633	Inhibition of NEK1 (unknown origin)	B	CN(C)[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H](c5ccc6ccncc6c5)[C@@]4(C)CC[C@@H]32)C1		CHEMBL4167193	>	IC50	nM	10000.0	CHEMBL5855	Homo sapiens	IC50	nM	10000.0
	22952924	CHEMBL4766861	Inhibition of recombinant human NEK1 (1 to 505 residues) assessed as residual activity at 10 uM using RLGRDKYKTLRQIRQ as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	11.0	CHEMBL5855	Homo sapiens	Activity	%	11.0
	23120758	CHEMBL4804443	Inhibition of NEK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	IC50	nM	6200.0	CHEMBL5855	Homo sapiens	IC50	uM	6.2
	23120759	CHEMBL4804443	Inhibition of NEK1 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1	Outside typical range	CHEMBL4860979	=	IC50	nM	-14100.0	CHEMBL5855	Homo sapiens	IC50	uM	-14.1
	23120760	CHEMBL4804443	Inhibition of NEK1 in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1	Outside typical range	CHEMBL4867931	=	IC50	nM	-9900.0	CHEMBL5855	Homo sapiens	IC50	uM	-9.9
	23120761	CHEMBL4804443	Inhibition of NEK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	30200.0	CHEMBL5855	Homo sapiens	IC50	uM	30.2
	23120762	CHEMBL4804443	Inhibition of NEK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	9300.0	CHEMBL5855	Homo sapiens	IC50	uM	9.3
	23120763	CHEMBL4804443	Inhibition of NEK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4859660	=	IC50	nM	-34000.0	CHEMBL5855	Homo sapiens	IC50	uM	-34.0
	23121796	CHEMBL4804625	Inhibition of NEK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	23121797	CHEMBL4804625	Inhibition of NEK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	23121798	CHEMBL4804625	Inhibition of NEK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	23121799	CHEMBL4804625	Inhibition of NEK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	23121800	CHEMBL4804625	Inhibition of NEK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	23121801	CHEMBL4804625	Inhibition of NEK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL5855	Homo sapiens	INH	%	0.0
	23122699	CHEMBL4805050	Inhibition of human NEK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	84.0	CHEMBL5855	Homo sapiens	Activity	%	84.0
	23123394	CHEMBL4805638	Inhibition of human NEK1 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	100.0	CHEMBL5855	Homo sapiens	Activity	%	100.0
	23123853	CHEMBL4806097	Inhibition of DNA-tagged human NEK1 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	92.0	CHEMBL5855	Homo sapiens	Activity	%	92.0
	23124878	CHEMBL4806655	Inhibition of human NEK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	80.0	CHEMBL5855	Homo sapiens	Activity	%	80.0
	23124879	CHEMBL4806655	Inhibition of human NEK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	96.0	CHEMBL5855	Homo sapiens	Activity	%	96.0
	23128359	CHEMBL4807928	Inhibition of NEK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL5855	Homo sapiens	Activity	%	75.0
	23128360	CHEMBL4807928	Inhibition of NEK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL5855	Homo sapiens	Activity	%	75.0
	23128361	CHEMBL4807928	Inhibition of NEK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL5855	Homo sapiens	Activity	%	75.0
	23290608	CHEMBL4839417	Inhibition of wild-type human partial length NEK1 (M1 to K278 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CSc1ccc(NC2=C(c3ccccc3Cl)C(=O)NC2=O)cc1		CHEMBL156563	=	Inhibition	%	75.0	CHEMBL5855	Homo sapiens	INH	%	75.0
	23312275	CHEMBL4844328	Inhibition of NEK1 (unknown origin) at 1 uM relative to control	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)C(O)(CC)CC2		CHEMBL4871593	=	Inhibition	%	75.0	CHEMBL5855	Homo sapiens	INH	%	75.0
Not Active	23317535	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	94.0	CHEMBL5855	Homo sapiens	% Control	%	94.0
Not Active	23318003	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23318670	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	80.0	CHEMBL5855	Homo sapiens	% Control	%	80.0
Not Active	23319153	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23319790	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23320265	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23320943	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23321411	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23322041	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	87.0	CHEMBL5855	Homo sapiens	% Control	%	87.0
Not Active	23322509	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23323198	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23323666	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23324520	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23325155	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	82.0	CHEMBL5855	Homo sapiens	% Control	%	82.0
Not Active	23325623	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23326270	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	93.0	CHEMBL5855	Homo sapiens	% Control	%	93.0
Not Active	23326738	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23327438	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23327906	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	96.0	CHEMBL5855	Homo sapiens	% Control	%	96.0
Not Active	23328493	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	95.0	CHEMBL5855	Homo sapiens	% Control	%	95.0
Not Active	23328961	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	97.0	CHEMBL5855	Homo sapiens	% Control	%	97.0
Not Active	23329444	CHEMBL4881151	NEK1(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	98.0	CHEMBL5855	Homo sapiens	% residual kinase activity	%	98.0
Not Active	23329907	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	85.0	CHEMBL5855	Homo sapiens	% Control	%	85.0
Not Active	23330375	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	97.0	CHEMBL5855	Homo sapiens	% Control	%	97.0
Not Active	23331131	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23331599	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23332186	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23332652	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23333370	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23334009	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	91.0	CHEMBL5855	Homo sapiens	% Control	%	91.0
Not Active	23334477	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23335456	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	96.0	CHEMBL5855	Homo sapiens	% Control	%	96.0
Not Active	23335924	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Slightly Active	23336551	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	44.0	CHEMBL5855	Homo sapiens	% Control	%	44.0
Not Active	23337019	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23337692	CHEMBL4882063	NEK1 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	104.5	CHEMBL5855	Homo sapiens	% Ctrl	%	104.5
Not Active	23338100	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23338568	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Slightly Active	23339180	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	45.0	CHEMBL5855	Homo sapiens	% Control	%	45.0
Not Active	23339648	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	53.0	CHEMBL5855	Homo sapiens	% Control	%	53.0
Slightly Active	23340285	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	45.0	CHEMBL5855	Homo sapiens	% Control	%	45.0
Slightly Active	23340753	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	45.0	CHEMBL5855	Homo sapiens	% Control	%	45.0
Not Active	23341410	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23341878	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23342494	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23342962	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Slightly Active	23343273	CHEMBL4882458	NEK1 Invitrogen selectivity data (BI)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Ctrl	%	49.0	CHEMBL5855	Homo sapiens	% Ctrl	%	49.0
Not Active	23343592	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23344060	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23344698	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23345271	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23345739	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23346316	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23346784	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	67.1	CHEMBL5855	Homo sapiens	% Control	%	67.1
Not Active	23347386	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	74.1	CHEMBL5855	Homo sapiens	% Control	%	74.1
Not Active	23347876	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23348455	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23348923	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23349510	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23350128	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23350596	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23351201	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23351669	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23352145	CHEMBL4882834	NEK1 Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	3.485	CHEMBL5855	Homo sapiens	% Inhibition	%	3.4852
Not Active	23352693	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23353161	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	83.0	CHEMBL5855	Homo sapiens	% Control	%	83.0
Not Active	23354043	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23354511	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23355243	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23355711	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23356347	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23356815	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23357424	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23358071	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	98.0	CHEMBL5855	Homo sapiens	% Control	%	98.0
Not Active	23358539	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23359125	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23359723	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23360191	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23360776	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Slightly Active	23361244	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	46.0	CHEMBL5855	Homo sapiens	% Control	%	46.0
Not Active	23361817	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23362353	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	54.0	CHEMBL5855	Homo sapiens	% Control	%	54.0
Slightly Active	23362821	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	41.0	CHEMBL5855	Homo sapiens	% Control	%	41.0
Not Active	23363290	CHEMBL4883261	NEK1 Kinase activity screen	B	CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1		CHEMBL4531334		Inhibition	%	25.08	CHEMBL5855	Homo sapiens	% inhibition	%	25.0806
Not Active	23363291	CHEMBL4883261	NEK1 Kinase activity screen	B	CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1		CHEMBL4531334		Inhibition	%	3.859	CHEMBL5855	Homo sapiens	% inhibition	%	3.8589
Not Active	23364463	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	77.0	CHEMBL5855	Homo sapiens	% Control	%	77.0
Not Active	23364931	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	99.0	CHEMBL5855	Homo sapiens	% Control	%	99.0
Not Active	23365670	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23366213	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23366803	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	84.0	CHEMBL5855	Homo sapiens	% Control	%	84.0
Not Active	23367271	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	58.0	CHEMBL5855	Homo sapiens	% Control	%	58.0
Not Active	23367667	CHEMBL4884020	NEK1 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	83.0	CHEMBL5855	Homo sapiens	% Residual activity with Skepinone-L	%	83.0
Not Active	23368149	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	84.0	CHEMBL5855	Homo sapiens	% Control	%	84.0
Not Active	23368617	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23369216	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	93.0	CHEMBL5855	Homo sapiens	% Control	%	93.0
Not Active	23369684	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	88.0	CHEMBL5855	Homo sapiens	% Control	%	88.0
Not Active	23370163	CHEMBL4884405	NEK1(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	102.0	CHEMBL5855	Homo sapiens	% residual kinase activity	%	102.0
Not Active	23370652	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23371120	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23371929	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	68.0	CHEMBL5855	Homo sapiens	% Control	%	68.0
Not Active	23372397	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	51.0	CHEMBL5855	Homo sapiens	% Control	%	51.0
	23372824	CHEMBL4884789	Nek1(NEK1LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL5855	Homo sapiens	pIC50		6.0
	23373233	CHEMBL4885080	Nek1(NEK1LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL5855	Homo sapiens	pIC50		6.0
	23373591	CHEMBL4885368	Nek1(NEK1LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL5855	Homo sapiens	pIC50		6.0
Not Active	23375053	CHEMBL4886041	NEK1 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	11.0	CHEMBL5855	Homo sapiens	% Inhibition	%	11.0
Slightly Active	23375824	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	40.0	CHEMBL5855	Homo sapiens	% Control	%	40.0
Not Active	23376292	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	55.0	CHEMBL5855	Homo sapiens	% Control	%	55.0
Not Active	23376869	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23377337	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23378197	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23378665	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23379832	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23380300	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	91.0	CHEMBL5855	Homo sapiens	% Control	%	91.0
Not Active	23380994	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
Not Active	23381642	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	59.0	CHEMBL5855	Homo sapiens	% Control	%	59.0
Slightly Active	23382110	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	48.0	CHEMBL5855	Homo sapiens	% Control	%	48.0
Not Active	23382734	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	75.0	CHEMBL5855	Homo sapiens	% Control	%	75.0
Not Active	23383202	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	51.0	CHEMBL5855	Homo sapiens	% Control	%	51.0
Not Active	23383898	CHEMBL4887515	NEK1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	92.0	CHEMBL5855	Homo sapiens	% Ctrl	%	92.0
Slightly Active	23383899	CHEMBL4887515	NEK1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	30.0	CHEMBL5855	Homo sapiens	% Ctrl	%	30.0
Not Active	23384375	CHEMBL4887970	NEK1(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	24.39	CHEMBL5855	Homo sapiens	% inhibition	%	24.39
Not Active	23384677	CHEMBL4888203	NEK1 SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	8.0	CHEMBL5855	Homo sapiens	% Inhibition	%	8.0
Not Active	23385117	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	94.0	CHEMBL5855	Homo sapiens	% Control	%	94.0
Not Active	23385584	CHEMBL4879841	KinomeScan assay: inhibition of NEK1	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL5855	Homo sapiens	% Control	%	100.0
